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Background：Human embryonic stem cells (hESCs) hold great promise for 
regenerative medicine due to their unlimited differentiation potential and 
proliferation capacity. Currently, potential clinical applications of hESCs are 
hampered by the use of mouse embryonic fibroblasts (MEF) and 
animal-derived components during culture. Experimental modifications and 
manipulations of hESCs require a feeder-free culture system to exclude the 
confounding effects of feeder cells. Recent literature have demonstrated the 
possibilities of culturing hESCs on autologous fibroblast, while others have 
also demonstrated an alternative of culturing hESCs on a feeder-free system 
with the aid of MatrigelTM. But none of them has systematically compared the 
supportive abilities of these various systems for long-term undifferentiated 
growth and pluripotency of hESC. In addition, animal origin of MatrigelTM 
necessitates the development of a feeder-free system with innovation of a 
xeno-free matrix.  
 
Hypotheses：The main hypothesis is that derivation of autologous feeder cells 
from hESCs can be optimized and the ECM derived from the autologous 
feeders can further support long-term undifferentiated growth of hESC in 




Methods: In this study, four sequential stages were conducted to prove our 
hypothesis.  
¾ Stage 1. Two sources of autologous fibroblasts were derived from H9 
hESCs with initial embryoid body (EB) formation (H9 ebF) or with direct 
differentiation (H9 dF).  
¾ Stage 2. The properties of autologous fibroblasts were characterized 
extensively by various assays.  
¾ Stage 3. The supportive abilities of these two sources of autologous 
fibroblasts were compared and characterized extensively, with MEF and 
feeder-free MatrigelTM supported systems as the controls.  
¾ Stage 4. The ECM substrate was extracted from the optimized autologous 
fibroblast cells and utilized to support growth of H1 and H9 hESC lines in 
the animal component free TeSRTM2 medium.  
 
Results: We found that both H9 dF and H9 ebF could support undifferentiated 
growth and morphology of hESCs for over 60 passages without chromosomal 
aberrations. Quantitative analysis demonstrated that hESCs cultured on H9 
ebF expressed higher level of hESCs-specific markers than H9 dF supported 
hESCs. The degree of differentiation in routine hESCs culture is lower in H9 
ebF culture system. The differentiation potential through acquisition of 
three-germ layer markers is higher in EB samples from H9 ebF systems than 




successfully supported normal growth of both H1 and H9 hESC lines for up to 
20 passages in serum-free and xeno-free condition. The undifferentiated state 
and pluripotency of hESCs cultured on autologous H9 ebF-derived ECM were 
comparable to MatrigelTM.  
 
Conclusions: In conclusion, autologous H9 ebF cells could serve as an 
optimal feeder system to support undifferentiated cell growth of H9 hESCs. 
We further developed a serum-free, xeno-free and feeder-free culture system 
to support growth of both H1 and H9 hESC lines by use of ECM extracted 
from H9 ebF. This study suggests a possible direction for the future 
improvement in hESC culture system. This study also advances the 
development of clinical-grade hESCs for both pre-clinical and clinical 
applications in future.  
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1.0. Introduction to Literature Review 
   
  Human embryonic stem cells (hESCs) hold great promise for future clinical 
applications because (1) they have unlimited self-renewal abilities and (2) they 
retain pluripotency to differentiate into all cell types of human body. Therefore, 
study of the cellular and molecular properties of hESCs provides information in 
the culture, differentiation and applications of hESCs. A review of the current 
signaling pathways helps us to understand the molecular mechanisms that 
regulate the pluripotency and differentiation of hESCs. Conventionally, mouse 
embryonic fibroblasts (MEF) are required to support long-term undifferentiated 
growth of hESCs. Understanding of molecular mechanisms provided by MEF 
helps us to improve existing culture system and develops a novel culture 
methodology for hESCs. In 2007, MatrigelTM matrix, which is an extracellular 
matrix (ECM) protein mixture secreted by mouse sarcoma cells, is developed to 
support feeder-free propagation of hESCs. Insights into ECM properties and 
functions facilitate future development of feeder-free and xeno-free culture 








1.1 Human embryonic stem cells (hESCs)  
 
“Stem cell” is a distinct type of cell that can renew itself and give rise to 
multiple specialized cell types [National institutes of health (NIH) stem cells 
report, 2001]. Depending on the developmental plasticity of the cell, it is 
classified into five categories, namely totipotent, pluripotent, multipotent, 
oligopotent and unipotent stem cells (see Table 1). 
 
 Table 1. Classification of stem cells regarding the developmental plasticity 
Categories Property Examples  
Totipotent  
Give rise to fully functional 
organisms as well as every cell 
type of the body (Sorgner, 2007).
Fertilized egg, blastomere 
Pluripotent 
Give rise to cells derived from all 
three embryonic germ layers, 
which are ectoderm, mesoderm 
and endoderm. Can not form a 
functional organism (Sorgner, 
2007). 
Embryonic stem cells 
Multipotent 
Give rise to limited types of cells 
which are in the closely related 
families (Sorgner, 2007). 
Mesenchymal stem cells, 
Hematopoietic stem cells 
Oligopotent Can differentiate into only a few cells (Sorgner, 2007). 
Lymphoid stem cells, 
Myeloid stem cells 
Unipotent 
Retain self-renewal capacity but 
can only produce one cell type 
(Sorgner, 2007). 
Muscle stem cells 
 
Apart from the plasticity, stem cells can also be classified into six broad 
groups according to their derivation sources, named embryonic stem cells 
 3 
Literature review 
(ESCs), embryonic germ cells, fetal stem cells, umbilical cord stem cells, adult 
stem cells and induced pluripotent stem (iPS) cells (Ariff Bongso, 2005, see 
Table 2). Each type of stem cells holds its own specific properties and 
advantages. Among them, ESCs are more advantageous than other stem cells in 
three ways: (1) ESCs have the ability to expand in vitro and maintain their 
normal phenotypes through infinite population doublings without chromosomal 
aberrations, providing a continuous and consistent source for research. (2) ESCs 
can differentiate into virtually all the cell types of the body, providing a valuable 
tool for differentiation and generation of broader range of cell types than other 
stem cells. (3) ESCs are naturally-isolated from health embryo at blastocyst 
stage and thus retain normal genotype without undesired genetic modifications.         
The iPS cells are firstly generated in 2006 by ShinyaYamanaka’s group at 
Kyoto University (Takahashi and Yamanaka, 2006) from mouse embryonic and 
adult fibroblast by a forced expression of four reprogramming factors: Oct4, 
Sox2, Klf4 and c-Myc using retrovirus system. In 2007, the same group 
reported a milestone achievement by creating iPS cells from human fibroblast 
using retroviral infection carrying the same four pivotal genes (Takahashi et al., 
2007). Another research group, led by James A. Thomson, independently used 
lentiviral system to reprogrammed human somatic cells into pluripotent stem 
cells (Yu et al., 2007) with partially overlapping combination: Oct4, Sox2, 
Nanog and Lin28. The iPS cells are similar to naturally-isolated ESCs, in 
respects to their self-renewing and pluripotent abilities, as well as the 
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expression of some cell surface markers, chromatin methylation patterns etc. 
However, such iPS cells contain a large number of viral vector integrations 
which could cause unpredictable genetic dysfunction (Kaji et al., 2009). 
Moreover, the over expression of inserted genes makes the created iPS cells be 
more prone to form tumors after injection in vivo (Knoepfler, 2009). Later on, 
some improved methods without viral integration were developed to address 
these questions, such as using non-integrating virus vectors (Fusaki et al., 
2009; Yu et al., 2009), transient-integrating lentiviruses (Soldner et al., 2009) 
and non-viral vector (Kaji et al., 2009). Two other methods: direct delivery of 
the reprogramming factors as proteins (Kim et al., 2009) or activation of the 
endogenous reprogramming factors by small molecules (Huangfu et al., 2008) 
are achieved to generate human iPS cells with elimination to the need for 
genetic modification (Kim et al., 2009; Zaehres et al., 2010). However, the 
above improvements suffer from low efficiency of successful induction. 
Moreover, a recent paper indicated that iPS cells are far more tumorigenic than 
ESC, suggesting a huge safety concern for therapeutical applications of iPS 
cells in future. Therefore, at the current stage, ESCs is the most promising 








Table 2. Characterization of stem cells by derivation source 
Category Source Property 
Embryonic stem cells 





capacity. Generate teratoma 
after injection into 
immunocompromised mice  
Embryonic germ cells Gonadal ridge (early fetal tissue) 
Pluripotent. Less 
proliferation capacity. 
Relatively limited range of 
potential fates compared to 
ES cells.  
 




Multipotent. Primitive cell 
types found in the organ of 









blood Multipotent. With potential 
to differentiate down 
mesenchymal lineage 





Adult stem cells Mature tissues or organs 
Multipotent. Found in adult 
tissues or organs that can 
self-renew themselves and 
differentiate to some or all 
the specific cells present in 
tissues or organs (Ratajczak 
et al., 2007).  
Induced pluripotent stem 
cells 
Reprogramming 
from somatic cells 
Pluripotent. Display 
unlimited proliferation 
capacity. Generate teratoma 
after injection into 
immunocompromised mice. 







1.1.1. Derivation of hESCs.  
 
ESCs were firstly described in 1981 by Martin from the University of 
California. The term “ESCs” was introduced to distinguish these 
embryo-derived pluripotent cells from teratocarcinoma-derived pluripotent 
embryonal carcinoma cells (Martin, 1981). Seventeen years later, Thomson JA 
and his coworkers firstly isolated hESCs from human blastocysts and 
successfully grew them in culture (Thomson et al., 1998). Since then, several 
labs have published the derivation of additional hESC lines, either using similar 
protocols (Amit and Itskovitz-Eldor, 2002; Lanzendorf et al., 2001; Reubinoff 
et al., 2000; Richards et al., 2002) or using embryos from other stages 
(Stojkovic et al., 2004; Strelchenko et al., 2004) despite the qualities and 
characteristics of the derived stem cell lines may vary (Hoffman and Carpenter, 
2005). So far, at least 225 hESC lines have been created, 75 eligible hESC lines 
are registered in NIH Stem Cell Registry.  
Originally non-clonally derived hESCs were maintained on irradiated or 
mitomycin C inactivated mouse embryonic fibroblasts (MEF) in 
serum-containing medium (Reubinoff et al., 2000; Thomson et al., 1998). 
Clonally-derived hESCs were later developed by Amit and colleagues (Amit et 
al., 2000), using refined serum-free culture medium composed of 20% of 
knockout serum replacer (Price PJ, 1998) and fibroblast growth factor-2 
(FGF-2). This refined condition maintains the pluripotency and proliferation 
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potential of hESCs for prolonged periods in culture. See Figure 1 for schematic 

























Figure 1. Schematic diagram of derivation of hESC lines from a human 
blastocyst. (Adopted from NIH stem cells report 2001)  
 
1.1.2. Characterization of hESCs 
 
Human ESCs are self-renewing and pluripotent with distinct colony 
morphology (Thomson et al., 1998). Self-renewal means hESCs are capable of 
going through divisions for unlimited period without differentiation. Human 
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ESCs also exhibit pluripotent capacities to give rise to derivatives of all three 
germ layers (ectoderm, mesoderm and endoderm) during development in vivo 
and culture in vitro (Reubinoff et al., 2000)  
Human ESCs have a doubling time of 35-40 hours and are characterized by 
the following criteria: (1) derivation from inner cell mass of human blastocyst, 
(2) propagation in vitro for unlimited passages with high telomerase activity 
(Amit et al., 2000), (3) grow in tightly compacted colonies with distinct border 
(Reubinoff et al., 2000; Thomson et al., 1998), (4) display high 
nucleus-to-cytoplasm ratio with prominent nuclei (Thomson et al., 1998), (5) 
maintain normal diploid karyotypes throughout extended culture periods, (6) 
retain stable developmental potential to differentiate into derivatives of all three 
germ layers (Reubinoff et al., 2000), (7) sustain high level of transcription 
factors Oct4 (Nichols et al., 1998), Nanog (Chambers et al., 2003) and Sox2 
(Avilion et al., 2003) (8) express hESC-specific cell surface markers, including 
stage-specific embryonic antigens (SSEA)-3, SSEA-4, Tumor recognition 
antigen (Tra)-1-60, Tra-1-80 and alkaline phosphatase (ALP) (Rosler et al., 
2004, Venable et al., 2005).  
 
1.1.2.1. Cell surface and molecular markers 
  
A panel of surface markers used to characterize hESCs also matches those of 
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human embryonal carcinoma cells or human preimplantation embryos 
(Andrews et al., 1984; Hoffman and Carpenter, 2005). They include 
glycosphingolipids, SSEA-3, SSEA-4, Keratan sulfate antigens, Tra-1-60, and 
Tra-1-81. Human ESCs also strongly express ALP, human antigen Thy1 and the 
class 1 major histocompatability antigens (MHC) and human leukocyte antigen 
(HLA)-A,B,C (Draper et al., 2002). Unlike mouse ES cells, hESCs do not 
express SSEA-1 antigen, suggesting the intrinsic differences between two 
species. In addition, expressions of hESC surface antigens are down-regulated 
during differentiation. Therefore, hESC-specific antigens can serve as markers 
to monitor the undifferentiated state and differentiation progress of hESCs both 
in vitro and in vivo (Bhattacharya et al., 2005).  
Despite the strong associations between these markers and the 
undifferentiated state of hESCs, the molecular functions of these antigens are 
still unclear. So far, no evidence shows the direct association between these 
surface proteins and the pluripotency of hESC (Brimble et al., 2007; Qiu et al., 
2008; Schopperle and DeWolf, 2007).  
A number of transcription factors have been found to play an essential role in 
maintaining the undifferentiated state of hESCs, and thus are used as markers to 
characterize hESCs (Hoffman and Carpenter, 2005). These include the three 
transcription factors (Oct4, Nanog and Sox2) that form the core regulatory 
network involved in the maintenance of pluripotency and the suppression of 
differentiation (Boyer et al., 2005). The transcription network that they are 
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involved will be discussed in section 1.1.4.   
 
1.1.2.2. Pluripotency of hESCs 
   
Pluripotency is one of the defining features of hESCs in the ability to 
differentiate into all derivatives of all three germ layers (Carpenter et al., 2003). 
The pluripotency of hESCs is assessed by embryoid body (EB) formation in 
vitro and teratoma formation in vivo after injection of hESCs into severe 
combined immunodeficiency (SCID) mice.  
EBs are three-dimensional (3-D) cell aggregates differentiated from ESCs in 
suspension condition. Differentiation is initiated upon aggregation and the cells 
to a certain extent recapitulate embryonic development in vivo (Funa, 2008). 
The differentiating cells acquired expression of molecular markers and 
characteristic morphologies specific to all three germ layers, but in an 
unorganized manner (Itskovitz-Eldor et al., 2000).  
When injected into a SCID mouse model, pluripotent hESCs result in 
teratoma formation, with the tissue structures from three germ layer, ectoderm, 
mesoderm and endoderm (Gschwend et al., 1987; Taori et al., 2006). The ability 
of teratoma formation is taken as the standard assessment of the pluripotency of 
hESCs in vivo (Brivanlou et al., 2003; Lensch et al., 2007).  
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1.1.3. Signaling pathways involved in the self-renewal and pluripotency of 
hESCs 
 
  Extrinsic and intrinsic factors work synchronically to regulate the 
self-renewal and pluripotency of hESCs. Orchestrated balance of extrinsic 
factors signaling pathways: FGF signaling, transforming growth factor-beta 
(TGF-β)/Activin signaling and BMP signaling are central to the self-renewal of 
hESCs (Bendall et al., 2007; Dvorak et al., 2005; James et al., 2005; Levenstein 
et al., 2006; Xiao et al., 2006; Xu et al., 2005b). A battery of transcription 
factors, including Oct4, Sox2 and Nanog, regulate the pluripotency of hESCs 
intrinsically (Biswas and Hutchins, 2007; Darr and Benvenisty, 2006). 
 
1.1.3.1. FGF signaling pathway 
 
FGF-2 is a key component to maintain the self-renewal and pluripotency of 
hESCs (Amit et al., 2000; Levenstein et al., 2006; Xu et al., 2001). FGF-2 is a 
prototype member of the FGF family. One low molecular mass (LMM, 
18-KaDa) FGF-2 and four alternative high molecular mass (HMM) FGF-2 
isoforms (22-, 22.5-, 24- and 34-kaDa) are encoded by a single copy of FGF2 
gene (Arnaud et al., 1999; Delrieu, 2000; Dvorak et al., 2006). Using cDNA 
microarray analysis and massively parallel signature sequencing, several 
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groups have detected that undifferentiated hESCs express elevated level of 
FGF-2 and all four types of FGF receptors, with FGFR1 as the most abundant 
receptor followed by FGFR4, FGFR3 and FGFR2 in the descending order 
(Dvash et al., 2004; Dvorak et al., 2005; Ginis et al., 2004; Rao et al., 2004; Sato 
et al., 2003; Sperger et al., 2003; Wei et al., 2005). Together, hESCs have been 
demonstrated to be well equipped to accept and transmit both exogenous and 
endogenous FGF signals. However, the understanding to the molecular 
mechanism of FGF-2 involved in the regulation of self-renewal and 
pluripotency of hESCs remains limited.  
In 1994, Quarto N. and Amalric F. reported that the exogenous FGF-2 
associated with heparin sulfate proteoglycans or their side chains and together 
bind to FGF receptors. The resulting ligand-receptor complex induces 
phosphroylation and activation of downstream signaling proteins that regulate 
cell proliferation, differentiation and adaptive response to in vitro conditions in 
hESCs (Dvorak et al., 2006; Stachowiak et al., 2003).  
Human ESCs can also synthesize FGF-2 isoforms with various molecular 
mass endogenously. Endogenous LMM FGF-2 is released in complex with 
various molecules and is exported to induce cellular signaling in an autocrine 
or paracrine manner in undifferentiated hESCs (Dvorak et al., 2005). On the 
other hand, endogenously synthesized HMM FGF-2 can associate with 
FGF2-interacting factor (FIF) and are directly transported to the nucleus where 
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mediates their pro-survival and anti-apoptotic activities (Dvorak et al., 2005; 
Dvorak et al., 2006).  
 
1.1.3.2. Crosstalk between FGF-2 signaling and other signaling pathways  
 
Other than FGF signaling, ligands of transforming growth factor beta 
(TGF-β) superfamily, such as bone morphology proteins (BMPs), growth 
differentiation factors (GDFs), Activin, Nodal, TGFβs, and ligands of Wnt 
family also participate in regulating the “stemness” of hESCs (Besser, 2004; 
Cadigan and Nusse, 1997; James et al., 2005; Nelson and Nusse, 2004; Wang 
et al., 2005a; Willert et al., 2003; Xiao et al., 2006; Xu et al., 2005b). The 
crosstalk between FGF-2 signaling and other signaling pathways have been 
studied by various groups. In 2005, Vallier L. and his colleagues reported that 
FGF-2 is a competent factor that cooperates with Nodal to support 
pluripotency of hESCs. In 2006, Xiao L. and his colleagues reported that 
Activin-A is necessary to maintain self-renewal of hESCs by inducing the 
expression of both Nodal and FGF-2. Additional studies demonstrated that 
FGF-2 can synergizes with noggin to repress trophoblast-inducing BMP 
signaling and thus sustains the undifferentiated growth of hESCs (Xu, R.H. et 
al., 2005; Wang, G. et al., 2005; Dvorak P., 2006, Greber B. et al., 2007). 
Together, FGF-2 is suggested to maintain self-renewal of hESCs by activation 
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of the Activin/Nodal/Smad2/3 branch and suppression of the 
BMP/GDF/Smad5 branch of the TGFβ-family signaling pathway (Greber et 
al., 2007).  
 
1.1.4. Transcription factors controlling self-renewal and pluripotency of 
hESCs.  
   
The self-renewing and undifferentiated state of hESCs is also maintained by 
the roles of transcription factors. The major transcription factors regulating 
pluripotency are Oct4, Sox2 and Nanog (Rodda et al., 2005). Therefore, the 
regulation for the expression of these factors is crucial to maintain the 
pluripotency of hESCs and the normal embryonic development (Gu et al., 
2005). However, the mechanism and the upstream factors that regulate the 
expression of these factors remain to be fully-elucidated.  
Oct4 (also called Oct3) is the best-characterized gene, which has been 
implicated to maintain pluripotency both in vivo and in vitro (Pan et al., 2002). 
Oct4 protein is a homodomain transcription factor of the POU family that is 
specifically expressed in all pluripotent cells (Herr et al., 1988; Scholer et al., 
1989) but not in the cells of differentiated tissues (Tai et al., 2005). Knocking 
out the Oct4 gene in mice causes early lethality due to the lack of ICM 
formation, indicating that Oct4 has a critical function for self-renewal of ES 
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cells (Chen et al., 2008; Nichols et al., 1998). Alteration in Oct4 expression 
promotes the differentiation and leads to the specification of ectoderm 
(Shimozaki et al., 2003), mesoderm (Niwa et al., 2000) and endoderm (Reim 
et al., 2004) primitive progenitors (Campbell et al., 2007), suggesting the 
regulatory effect of Oct4 in the maintenance of pluripotency of stem cells. 
Expression of Oct4 is regulated at a transcription level by both the cis-acting 
elements which are located upstream of the Oct4 gene and the methylation of 
chromatin structure within the regulatory region (Ben-shushan et al., 1993; 
Pan et al., 2002). Once being activated, Oct4 protein works together with other 
transcription factors to regulate the expression of specific target genes at 
different defined stages. The most common co-operators of Oct4 are Sox2 and 
Nanog. Several downstream target proteins of Oct4 have been identified. They 
include fibroblast growth factor-4 (FGF-4), secreted phosphoprotein-1 (SPP1), 
F-box protein-15 (FBXO15) and left right determination factor-1 (Lefty1) and 
so on (Babaie et al., 2007; Boiani and Scholer, 2005; Nakatake et al., 2006).  
Sox2, a transcription factor bearing high-mobility-group (HMG) box, is in 
cooperation with Oct4 to regulate the pluripotency of hESCs 
(Facucho-Oliveira and St John, 2009). Sox2 expression is under the control of 
Oct4-Sox2 complex (Tomioka et al., 2002). However, Unlike Oct4, expression 
of Sox2 is also found in the multipotent cells of the extraembryonic ectoderm 
and in the precursor cells of the developing central nervous system, suggesting 
a role for Sox2 in preserving developmental potential (Fong et al., 2008). 
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Nanog is another transcription factor which is essential for the process of 
self-renewal in hESCs (Avery et al., 2006). Nanog protein is a homeobox 
transcription factor which functions in concern with Oct4 and Sox2 to 
maintain the pluripotent activity of hESCs (Jaenisch and Young, 2008; Zhou et 
al., 2009). Similar to Oct4, Nanog expression is restricted to pluripotent cells 
and is down-regulated after differentiation (Pan and Thomson, 2007). Previous 
studies reported that the expression of Nanog is regulated by synergic binding 
of Oct4 and Sox2 to the Nanog promoter where contains Oct4/Sox2 motif 
(Kuroda et al., 2005; Rodda et al., 2005).  
 
1.2. Long-term maintenance of hESCs in culture 
 
1.2.1. Maintenance of hESCs on MEF feeder 
 
  MEF are isolated from 12.5 to 13.5 days fetus (Robertson, E.J. 1987). They 
provide substrate support for the growth of hESCs through expression of 
adhesion molecules and production of extracellular matrix (ECM). They also 
produce growth factors, such as heparan sulfate proteoglycans and pigment 
epithelium derived factor into culture medium or to ECM so as to maintain the 
undifferentiated state of hESCs (Levenstein et al., 2008; Xie et al., 2004). 
Although the use of MEF as a feeder layer to support undifferentiated growth 
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of hESCs is the most conventional method adopted worldwide, the molecular 
basis for this is still incompletely understood.  
  Proteomic analysis of conditioned medium produced from MEF feeder 
demonstrated the presence of differentiation and growth factors [e.g. 
insulin-like growth binding protein (IGFBP)-4], metabolic enzymes (e.g. 
nucleoside diphosphate kinase A/B), cytoskeleton proteins (e.g. β-actin, lamin 
A/C), ECM and remodeling proteins (e.g. collagen α1 (IV) chain, 
stromelysin-1), and signaling transduction factors (e.g. Growth factor receptor 
bound protein 2) etc (Lim and Bodnar, 2002). The comparison between 
supportive and non-supportive MEF indicated the exclusive production of 
certain factors by supportive MEF. These factors include pigment epithelium 
derived factor (PEDF) and IGFBP-5, which participate in regulation of growth 
stimulation or differentiation; as well as AMDA25 and matrix 
metalloproteinase-14 (MMP14), which have been reported to play a role in 
embryogenesis (Chin et al., 2007; Houenou et al., 1999; Salih et al., 2004; 
Tombran-Tink and Johnson, 1989; Zhu et al., 1999).  
In addition, antibodies-based protein array system further demonstrated the 
presence of some cytokines in supportive MEF conditioned medium but not or 
expressing low in non-supportive MEF conditioned medium, including 
LIF-regulated monocyte chemoattractant protein-1 (MCP-1) and IL-6 (Chin et 
al., 2007; Ernst et al., 1996; Mellado et al., 1998). Leukemia inhibitory factor 
(LIF) has been discovered to maintain the pluripotency of mouse embryonic 
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stem cells in feeder-free culture through activation of LIF/gp130/STAT3 
pathway (Okita and Yamanaka, 2006; Smith and Hooper, 1987), but failed to 
maintain properties of hESCs in culture (Thomson et al., 1998). Likewise, 
IL-6 secreted by MEF is not responsible for the maintenance of pluripotency 
of hESCs since murine IL-6 does not act on human receptor (Humphrey et al., 
2004). In addition, production of TGFβ1, activin A and BMP-14 but not 
FGF-2 by supportive MEF feeders was also reported by another group 
(Eiselleova et al., 2008). Therefore, MEF culture system required addition of 
FGF-2 in the conditioned medium to retain pluripotency in hESCs.  
  Although MEF have been routinely used as feeder cells to support hESCs 
culture, the use of MEF still pose difficulties for future possible clinical 
applications of hESCs. For example, MEF have limited life span and normally 
reach senescence after 7 to 8 passages. The qualities of MEF from different 
batches vary significantly and thus require extensive testing before use. 
Moreover, the preparation of supportive MEF is time consuming and requires 
heavy labors. Using MEF also increases the risk of contaminating human cells 
with animal pathogens and viruses (Cobo et al., 2008). These limitations 
encourage researchers to explore alternative culture methods, with the aim to 
devise a xeno-free culture system for hESCs expansion.  
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1.2.2. Maintenance of hESCs on human feeder layers 
 
  In recent years, in order to derive clinical-grade hESCs in xeno-free 
condition, a concentrated effort has been made to replace the conventional 
MEF feeder with feeder cells derived from human origin. Two main 
progresses have been made. One is the use of human feeder cells derived from 
human tissues. In 2002, Richard et al reported the successful propagation of 
hESCs on fetal muscle fibroblasts with the addition of insulin transferring 
selenium G supplement in the culture medium (Richards et al., 2002). In the 
next year, the same group reported the use of adult skin fibroblast cells 
established from abdominal skin biopsies to support the prolonged 
undifferentiated growth of hESCs (Richards et al., 2003). In the same year, 
another group discovered the possibility of co-culturing undifferentiated 
hESCs with human adult marrow stromal cells from multiple donors (Cheng et 
al., 2003). Besides that, human foreskin fibroblast (Amit et al., 2003; 
Ellerstrom et al., 2006; Hovatta et al., 2003; Inzunza et al., 2005; Kumar et al., 
2009; Tecirlioglu et al., 2010), uterine endometrium cells (Lee et al., 2005) 
and human placenta fibroblasts (Genbacev et al., 2005) have also been found 
to be supportive for long-time propagation of hESC culture. However, 
non-supportive human feeder cells have also been reported in previous studies, 
including fetal lung cells, adult fallopian tubal epithelial cells and adult muscle 
cells (Richards et al., 2003). Transcriptome analysis of different human feeder 
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cells suggested distinct differences between supportive and non-supportive 
feeders (Kueh et al., 2006). A number of ECM components (collagen type I, 
III and V, fibronectin 1, heparin sulfate proteoglycan 2 and hyaluronan 
synthase 2) and some growth factors (Gremlin, follistatin-like 1, disintegrin 
and UGFBP) were up-regulated in supportive feeders. These findings 
suggested the important role of ECM and growth factors in maintaining the 
undifferentiated state of hESCs.  
Proteome analysis of conditioned medium from human forskin fibroblasts 
further demonstrated the production of FGF-2, IGFBP-3, IGFBP-6 (Eiselleova 
et al., 2008; Prowse et al., 2005). The feeder cell-produced FGF-2 in turn 
activates signaling pathways in hESCs and plays a key role in the maintenance 
of self-renewal and undifferentiated growth of hESCs. Recent evidence also 
pointed to a cooperative activity of IGF and FGF-2 in establishing the 
regulatory stem cells niche of pluripotent hESCs in vitro (Bendall et al., 2007). 
All the above findings suggested the feasibility of using human feeders to 
support long-term growth of hESCs.  
However, some drawbacks exist in these human culture systems. Firstly, 
using human feeder cells derived from donated human tissues may raise huge 
ethical concerns (Heng et al., 2004). Secondly, the life span of primary human 
feeder cells is also limited (Meng et al., 2008). Therefore, the availability and 
high variability of human feeder cells from donated adult tissues could 
influence the consistency and the reliability of the hESCs cultured on them, 
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compromising the good quality control in laboratories. Thirdly, using human 
tissues donated from patients or biopsies may cause contamination in the 
culture with unknown or unscreened pathogens of unknown or rarely 
emerging human diseases (Heng et al., 2004; Stacey et al., 2006). Therefore, a 
more consistent, standardized and pathogen-free feeder cell source derived 
from human origin is required for large-scale propagation of hESCs.    
 
1.2.3. Maintenance of hESCs on autologous feeder layers derived from hESCs  
 
Another achievement in the improvement of hESC culture system is the use 
of autologous feeder cells derived from hESCs themselves. As early as 2005, 
three individual groups reported the successful employment of fibroblast-like 
cells derived from hESCs to support undifferentiated growth of hESCs 
(Stojkovic et al., 2005b; Wang et al., 2005b; Yoo et al., 2005). In 2006, another 
group reported the use of mesenchymal stem cells (MSC) differentiated from 
hESCs to support hESC growth (Olivier et al., 2006). Two years later, 
Saxena’s group reported the novel FGF-2 secreting human fibroblast feeder 
cells from hESCs (Saxena et al., 2008). Similarly, hESC-derived MSC and its 
conditioned media were shown to support undifferentiated growth of hESCs in 
both feeder and feeder-free conditions (Choo et al., 2008; Lian et al., 2007).  
Superior to human feeder cells derived from human donors, fibroblast-like 
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cells differentiated from hESCs are autogenic, and thus have ability to 
replenish a relatively homogenous and consistent source of feeder cells in the 
culture platform (Fu et al., 2009). It also eliminates the concern of 
contamination of infectious human pathogens from donors. 
 Two approaches were described in previous studies to develop autologous 
feeder cells from hESCs. One was established from the outgrowth of EBs 
differentiated from hESCs (Saxena et al., 2008; Wang et al., 2005b). EB 
formation has been reported to initiate differentiation of hESCs which 
recapitulates embryonic development (Boyd et al., 2007; Feraud et al., 2001; 
Itskovitz-Eldor et al., 2000; Risau et al., 1988, Fu et al., 2009). Therefore, the 
derivation of fibroblast cells from EB outgrowth to some extent resembles the 
derivation procedure of MEF. The other was through direct differentiation 
from hESCs without EB formation (Stojkovic et al., 2005b; Yoo et al., 2005). 
Both of these two methods can successfully develop supportive feeder cells 
for prolonged growth of hESCs. However，there was no systematic study to 
compare the supportive abilities of these two autologous feeder cells, nor 






1.2.4. Maintenance of hESCs in feeder-free system 
 
1.2.4.1. Components and functions of ECM derived from feeder cells  
 
Fibroblasts secrete and organize the ECM, which provides structural 
support for their adhesion, migration, and tissue morphogenesis, in addition to 
regulating cellular functions such as growth and survival (Beacham et al., 
2007; Buck and Horwitz, 1987; D.Hay, 1991; Geiger et al., 2001; Hynes, 
1999). Human ESCs can express cell surface receptors known as integrins. 
The integrins can mediate adhesion between hESCs and feeder-derived ECM, 
and also trigger various intracellular signaling pathways that involved in cell 
proliferation, apoptosis, shape, polarity, motility, gene expression and 
differentiation (Amit et al., 2004; Hynes, 2002). ECM is an intricate network 
of macromolecules consisting of two main classes of extracellular 
macromolecules. (Bruce Alberts, 2002). One class is called 
glycosaminoglycans (GAG), such as heparin sulfate, which is usually linked to 
proteins in the form of proteoglycans. The other is fibrous proteins, including 
collagen, fibronectin and laminin, etc.  
Proteoglycan is thought to have a major role in chemical signaling between 
cells. For example, the heparin sulfate chains of proteoglycans can bind to 
FGFs and stimulate proliferation of cells (Reiland and Rapraeger, 1993). They 
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also act as co-receptors that collaborate with cell-surface receptors and initiate 
response of cells to extracellular signal proteins (Bruce Alberts, 2002).  
Fibrous proteins contribute to organizing the matrix and helping cells to 
attach (Bruce Alberts, 2002). Particularly, laminin has been identified to 
promote hESC assembly (Evseenko et al., 2009). Fibronectin was reported to 
act through α5β1 integrin receptors and trigger signal transduction cascades 
that modulate proliferation of hESCs (Amit et al., 2004; Braam et al., 2008) 
  
1.2.4.2. ECM components from animal origin    
 
In 2001, a concept of culturing hESCs on feeder-free system has been raised 
out by Xu and colleagues (Xu et al., 2001), via replacing the feeder cells with 
MatrigelTM, which is an ECM protein mixture secreted by mouse Engelbreth 
Holm-Swarm sarcoma cells (Kleinman et al., 1982), and 100% MEF feeder 
conditioned medium. The major components of MatrigelTM matrix are laminin, 
collagen IV, entacin and heparin sulfate proteoglycan (Bissell et al., 1987; 
Kleinman et al., 1982). Other undefined components, such as growth factors, 
collagenases and plasminogen activators have also been reported (McGuire 
and Seeds, 1989; Vukicevic et al., 1992). Although this system can support 
continuous growth of hESCs for more than one year and maintain hESC 
features, some significant disadvantages still exist. The major disadvantage is 
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the use of MEF conditioned medium, which increase the risk of exposure to 
animal pathogens. Moreover, a portion of hESCs in this culture system were 
found to be differentiated and could serve as “auto-feeders” for the 
maintenance of hESCs in culture (Amit and Itskovitz-Eldor, 2006). Later on, 
this system was improved by the same group on the basis of MatrigelTM matrix 
and culture medium supplemented with serum replacement and 40ng/ml 
FGF-2 (Xu et al., 2005a) or with addition of high level of Noggin (Xu et al., 
2005b). Several other groups also reported feeder-free culture of hESCs on 
MatrigelTM matrix in media with different formulations (Lu et al., 2006; 
Sjogren-Jansson et al., 2005; Vallier et al., 2005; Yao et al., 2006). Two 
commercial media, mTeSR®1 (Ludwig et al., 2006) and STEMPRO (Wang et 
al., 2007b), were utilized and reported to be supportive for feeder-free culture 
of hESCs. However, all the above-mentioned approaches were based on 
MatrigelTM, which is an animal-derived product containing an undefined 
variety of components. MatrigelTM is also reported to be most likely associated 
with ill-defined mixture of growth factors, and is prone to batch variations 
(Furue et al., 2008).  
In 2005, Klimanskava and colleagues were first to report the derivation of a 
new feeder-free hESC line with use of MEF-produced ECM (Klimanskaya et 
al., 2005). In this new system, ECM was prepared by sodium deoxycholate 
extraction of MEF cell monolayer. The culture medium was supplemented 
with plasmanate, human LIF and FGF-2. Successful use of feeder-derived 
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ECM to support the growth of hESCs opened a new window for developing 
feeder-free systems for hESCs. A few years later, another group reported 
long-term undifferentiated growth of hESCs on porcine collagen I with 
presence of heparin in the culture medium (Furue et al., 2008). More recently, 
porcine gelatin alone was also applied to support clonal expansion of hESCs 
with combination of a selective Rho-associated Kinase (ROCK) inhibitor, 
Y-27632 and soluble fibronectin in culture medium (Kitajima and Niwa, 
2010). The use of Y-27632 has been reported to enhance interactions between 
hESCs and ECM (Li et al., 2009a; Pakzad et al., 2010). All the 
above-mentioned strategies strongly suggest the potential use of 
fibroblast-derived ECM and ECM proteins for feeder-free propagation of 
hESCs. However, the use of MatrigelTM, MEF-derived ECM, porcine collagen 
I and porcine gelatin as stratum for hESCs culture hampers the future clinical 
applications of hESCs because of the risk of contaminations by animal 
pathogens in culture and graft injection, immunoreactions and viral or 
bacterial infections after transplantation into patients (Cobo et al., 2005; 
Martin et al., 2005; Rajala et al., 2010; Sjogren-Jansson et al., 2005; Skottman 
and Hovatta, 2006).  
 




  Ideally, the culture method for hESCs should be a combination of a 
xeno-free and feeder-free culture system (Amit and Itskovitz-Eldor, 2006). To 
achieve this, many defined systems have been reported. One group has 
described a novel method of using human serum-coated plate and medium 
conditioned by fibroblast cells differentiated from hESCs (Stojkovic et al., 
2005a). However, for continuous culture of hESCs, human serum will be 
needed frequently. Human serum from different human sources is largely 
undefined and is likely to cause variations in cell culture. Moreover, 
preparation of human serum from human donors may increase the risk of 
contaminations with unknown or rare infectious human pathogens.  
  There are some recent advances in the use of ECM components derived 
from human sources. Amit and colleagues reported the possibilities of 
culturing hESCs on human fibronectin matrix with 15% serum replacement in 
the presence of TGF-β1 and FGF-2 (Amit et al., 2004; Amit and 
Itskovitz-Eldor, 2006; Amit, 2004). Other studies also described the 
undifferentiated culture and maintenance of hESCs on human laminin in 
culture medium supplemented with either activin A (Beattie et al., 2005) or a 
cocktail of growth factors, including human FGF-2, human stem cell factor, 
human flt3 ligand and human LIF (Li et al., 2005). In 2006, Liu et al 
published the growth of hESCs on human matrices combined with a novel 
chemical defined medium containing human ECM proteins, FGF-2 and 
N2B27 (Liu et al., 2006). Under these conditions, hESCs maintain typical 
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features of undifferentiated state and achieve long-term propagation. However, 
the supportive efficacy of these systems varies among different laboratories 
and some reagents have disparities according to lots, which may influence the 
standardization and compromise good quality control for large scale 
propagation of hESCs (Akopian et al., 2010; Lu et al., 2006).  
In the same year, Ludwig’s group reported the first feeder-free and 
xeno-free derivation of two hESC lines using a defined combination of four 
human ECM proteins (collagen IV, fibronectin, laminin and vitronectin) as 
attachment matrix and a defined xeno-component free culture medium called 
TeSR1 (Ludwig et al., 2006). However, both of the derived hESC lines were 
found to be karyotypically abnormal in long-term culture (Hakala et al., 2009; 
Moore, 2006). Investigations suggested that the selective pressures in the 
culture medium, the balance of growth factors and other important parameters 
such as ECM, cell dissociation methods and oxygen tension may be crucial to 
determine the genomic stabilities of hESCs (Moore, 2006). Therefore, correct 
formulation of medium without imposing pressure and substrate that resemble 
nature microenvironment will be essential to provide a robust platform for 
feeder-free culture of hESCs.  
Most recently, one group reported that ECM isolated from human foreskin 
fibroblasts can support long term xeno-free culture of hESCs with the 
presence of 100ng/ml recombinant FGF-2 in the HEScGRO basal medium 
(Meng et al., 2010). They employed ROCK inhibitor Y-27632 in medium to 
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increase plating efficiency during passage. This discovery provides a new 
insight to the use of ECM isolated from primary human fibroblasts to support 
long-term growth of hESCs. However, as discussed previously, the 
employment of fibroblasts originated from human donors makes it less 
suitable for expanding clinical-grade hESCs. The supplementation of high 
dose of growth factors also increases the cost of routine culture of hESCs in 
the long run. Although quite a number of publications have demonstrated the 
advantageous effect of ROCK inhibitor on enhancing the survival rates of 
disassociated hESCs, there is still no comprehensive study to investigate the 
long-term effect of this chemical on the morphology, the biochemical 
properties and the genetic stabilities of hESCs. ROCKs are serine/theonine 
kinases that are involved in many aspects of cell motility and cellular 
processes (Riento and Ridley, 2003). They can be activated by Wnt-dependent 
planar cell polarity (PCP) pathway and in turn phosphorylate several 
substrates leading to various cellular response, including cell contraction, actin 
network assembly, focal adhesion and growth-cone collapse (Riento and 
Ridley, 2003). Therefore, the use of ROCK inhibitor in long term may trigger 
undesired effects to hESCs, which need further investigations.  
 
1.2.4.4. Growth of hESCs in suspension 
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  In 2008, Phillip and colleagues described a novel suspension-based 
expansion of hESCs on collagen-coated microcarriers (Phillips et al., 2008). 
However, this group did not test the genomic integrity of hESCs grown on 
microcarriers after multiple passages. One year later, another group reported a 
successful scale-up of hESC production in a stirred microcarrier culture 
system with MEF-conditioned medium (Fernandes et al., 2009). Human ESCs 
are shown to maintain normal karyotype after 2 weeks in this stirred 
microcarrier system. However, the use of MEF conditioned medium reduces 
the significance of this culture system in derivation and expansion of 
clinical-grade hESCs. Furthermore, the genomic integrities of hESCs were 
only characterized 2 weeks after culture, which is definitely not convincing 
enough. Cytogenetic analysis of long-term cultures is necessary to confirm the 
genomic stabilities of hESCs in this suspension-based system.   
  Most recently, Steiner’s group reported a new technology for derivation, 
propagation and differentiation of hESCs in suspension that do not involve 
feeder cells or microcarriers (Steiner et al., 2010). In this study, several factors 
were added, including ECM proteins, neurotrophic factors, FGF-2 and activin 
to promote continuous propagation of hESCs without differentiation. The 
novel culture medium also supported the derivation of three new hESC lines. 
The researcher demonstrated the capability to induce differentiation of hESCs 
in suspension. This discovery proposes a new route to large-scale expansion of 
hESCs for future cell therapies. However, one cell line (HES1) propagated in 
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suspension was identified as genomic abnormal. This abnormality may be 
related to suboptimal culture conditions, which warrants further improvements 
and investigations. In addition, human source or recombinant ECM proteins 
are expensive and vary from batch to batch (Hakala et al., 2009). The 
supplementation of growth factors also increases the cost of cell culture and 
makes the strategy less cost-effective for routine and large-scale propagation 
of hESCs.      
 
1.3. Applications of hESCs 
 
Due to the self-renewing and pluripotent differentiation properties, hESCs 
are considered to hold great potential for future clinical applications, including 
regenerative medicine and cytotoxicity testing etc, and cellular model for basic 
science study. 
 
1.3.1. Regenerative medicine and cell therapy 
 
Human ESCs offer an exciting opportunity for translational research in 
regenerative medicine. Table 3 summarizes a list of reported specialized cell 
types differentiated from hESCs. These hESC-derived somatic cells offer the 
possibility of providing cell and tissue replacements to treat diseases including 
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Parkinson’s disease, spinal cord injury, retinal degeneration, burns, heart 
diseases, diabetes, osteoarthritis, etc. For instance, the differentiation of hESCs 
into insulin-secreting pancreatic beta cells can be used to treat patients with 
type II diabetes (Baetge, 2008; Brolen et al., 2005; Cho et al., 2008; Kroon et 
al., 2008). The generation of functional dopaminergic neurons from hESCs 
has been showed to have therapeutic effects on Parkinsonian rats in vivo 
(Geeta et al., 2008). Recent transplantation studies in preclinical rodent 
models have provided exciting proof-of-principle for the use of hESC-derived 
cardiomyocytes in infarct repair and in the formation of a "biological 
pacemaker" (Shiba et al., 2009). The hESC-derived endothelial cells may have 
potential therapeutic applications for the repair of ischemic tissues and the 
construction of tissue-engineered vascular grafts (Li et al., 2009b). Recently 
the hESC-derived chondrogenic cells have been proved to be efficient for 
cartilage repair in an osteochondral defect rat model (Toh et al., 2010a). 
However, the purity, tumorigenicity, immunogenicity and genetic stability of 
specialized cells differentiated from hESCs remain to be addressed in the 
laboratories before they can be used in clinics (Puceat and Ballis, 2007).  
  Particularly, hESCs can provide promising cell sources for regeneration of 
some craniofacial tissues, such as teeth, oral epithelium, salivary glands etc. 
The embryonic origin of hESCs allows them to serve as a more convinced 




Table 3. Overview of specific cell types differentiated from hESCs 
Cell type Potential applications (Reference) 
Extra-embryonic lineage 
Trophoblast Study early embryonic development (Gerami-Naini et al., 2004; Xu et al., 2002) 
Ectoderm 
Keratinocyte Skin substitute, epidermis graft (Green et al., 2003; Guenou et al., 2009) 
Oligodendrocyte  Treating neurodegenerative diseases and spinal cord injuries to the adult CNS (Nistor et al., 
2005; Sharp et al., 2010) 
Neuron and astrocyte Treatment for Parkinson’s disease (Ko et al., 2007; Zhang et al., 2001) 
Glia Neuronal replacement (Nat et al., 2007) 
Melanocyte Study model for dermatopathology, albino (Fang et al., 2006; Zabierowski and Herlyn, 2010) 
Retinal neuron/cells Treatment of retinal degenerations (Lamba et al., 2006; Nistor et al., 2010) 
Motor neuron Cell therapy for motor neuron disease (Lim et al., 2006; Wada et al., 2009) 
Mesoderm 
Cardiomyocyte Treatment for heart disease, (Kehat et al., 2001; Pekkanen-Mattila et al., 2010) 
Chondrocyte Cartilage repair (Toh et al., 2010b; Vats et al., 2006) 
Endothelial cell Therapeutic vascularization and tissue engineering (Kane et al., 2010; Nourse et al., 2010; 
Wang et al., 2007c) 
Smooth muscle cell Provide physical support to the vasculature and increase implantation efficiency (Huang et al., 
2006; Vo et al., 2010) 
Adipocyte Plastic surgery (Xiong et al., 2005) 
Osteoblast Skeletal tissue repair (Bielby et al., 2004; Smith et al., 2010) 
Dendritic cells (DC) Scalable source of cells for DC vaccines to treat malignancy; immunotherapy (Slukvin et al., 
2006; Tseng et al., 2009) 
Megakaryocyte (MK) Exploration of the molecular basis of MK commitment and differentiation (Gaur et al., 2006; 
Klimchenko et al., 2009) 
Natural killer cell For analysis of early stages of human hematopoiesis and evaluation of lymphocyte 
development(Woll et al., 2005; Yen et al., 2009) 
Erythrocyte Donorless source for blood supply and cell therapy  (Chang et al., 2006; Lu et al., 2010) 
Macrophage HIV gene therapy (Anderson et al., 2006) 
Germ cells Understanding to the molecular regulation of human germ cell development (Clark, 2007; Kee 
et al., 2006) 
T cells Treatment of T cell disorders (Galic et al., 2006; Timmermans et al., 2009) 
Endoderm 
Hepatocyte Liver repair(Lavon et al., 2004; Touboul et al., 2010) 
Insulin producing 
endocrine cell 
Pancreatic hormone production for diabetes treatment (Cai et al., 2010; D'Amour et al., 2006) 
Lung alveolar 
epithelial type II cells 
Treatment acute lung injury(Wang et al., 2007a; Wang et al., 2010) 
Type II pneumocytes Therapeuty or construction of an in vitro model of human lung (Samadikuchaksaraei et al., 
2006) 
Prostate tissue Study model to treat prostate enlargement in aged men (Taylor et al., 2006) 
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1.3.2. Cytotoxicity testing, embryotoxicity screening and drug discovery 
 
In the current stage, immortalized cell lines and live animal models are 
commonly used for cytotoxicity screening of biomedical devices and materials 
(Cao et al., 2008). However, the abnormal genotypes of immortalized cell 
lines and cross-species variations between animals and human beings hinder 
the extrapolation of the cytotoxicity for relevance on humans. Therefore, 
hESCs and its differentiated somatic progenitors have been proposed to be 
good models for cytotoxicity and genotoxicity testing. For example, our 
previous study reported that the cytotoxic response of hESC-derived 
fibroblasts to mitomycin C was more sensitive than traditionally immortalized 
cell line L929 (Cao et al., 2008).  
Moreover, pluripotent hESCs can recapitulate cellular developmental 
processes and gene expression patterns of early embryogenesis during in vitro 
differentiation (Rohwedel et al., 2001). Therefore, hESCs and their derivatives 
are also better suited to analyze embryotoxic effect of chemical compounds 
and substances as in vitro models (Krtolica et al., 2009; Mehta et al., 2008). 
For instance, one study provided new insights into the effects of ethanol on 
human embryogenesis and neuroprogenitors by using neurons differentiated 
from hESCs, offering an opportunity to delineate potential therapeutic 
strategies to restore early ethanol-induced brain damage (Talens-Visconti et al., 
2010). An ECVAM (European center for the validation for the alternative 
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methods) report showed that ES cells was ready for the assessing the 
embryotoxic potentials of chemicals for regular purposes (Genschow et al., 
2004).  
Human ESCs and their derivatives also represent an effective and dynamic 
cellular system suitable for drug development, which can be tested in vitro for 
safety or to predict potential toxicity in humans (Davila et al., 2004; Wobus 
and Boheler, 2005). For example, Flora’s group firstly provided experimental 
evidence suggesting that hESCs could be utilized in studying the efficacy of 
monoisoamyl dimercaptosuccinic acid in a comparable manner with animal 
models (Flora and Mehta, 2009). Recently, an assay system for drug-induced 
Q-T interval prolongation using hESC-derived cardiomyocytes has been 
developed (Asai et al., 2010).  
 
1.3.3. Cellular model for basic science study 
 
Apart from clinical applications, applications of hESCs for basic science 
research are also important. They can be used as a basic research tool to 
understand the development and the function of human tissues. The study of 
human developmental biology is particularly constrained by practical and 
ethical limitations (Audrey R. Chapman, 1999). Human ESCs open a new 
window to allow scientists to investigate how human cells commit to a 
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specific lineage. They also provide a new model to understand the molecular 
basis, the regulation process and the mechanisms of various human diseases, 
which would undoubtedly help to devise innovative strategies for the 
treatment of diseases.   
 
1.4. Towards clinical-grade hESCs  
   
  In summary, the culture of hESCs is limited with respect to clinical 
potential by the use of MEF as a feeder layer and animal-derived components 
in culture medium. These concerns lead to intensive investigations for 
developing alternative culture strategies which are ideally xeno-free, 
pathogen-free and feeder-free. One major advantage is the possibility of 
culturing hESCs on the feeder cells derived from themselves. The other major 
advantage is the successful propagation of hESCs in a feeder-free system with 
aid of human ECM components and defined medium. So far, it is hard to tell 
which one of these two directions is more sophisticated and advantageous 
because both of them have their own limitations. For the current proposed 
feeder-free culture methods, there is a clear indication that hESCs cultured 
without feeder cells in long-term cultures may be more prone to undesirable 
abnormalities caused by suboptimal culture conditions and enzymatic 




2010). Therefore, it is reasonable to believe that at the current stage, the goal 
to develop clinical-grade hESCs should be focused on the development and 
use of standardized and qualified autologous human feeder cells (Rajala et al., 
2010).  
However, feeder culture conditions are often problematic for the 
experimental manipulations of hESCs. For example, to obtain stable hESC 
lines with integration of transgenes, drug selection is applied. Therefore, the 
feeder cells are required to carry the same drug-resistant genes to support the 
growth of hESC in a drug-conditioned medium. Such situation may restrict the 
application of multiple transgenic manipulations on hESCs, but not be the case 
in a feeder-free system. Moreover, employment of feeder cells may comprise 
the effect of exogenous factors on self-renewal and differentiation of hESCs. 
For toxicity testing and drug screening, use of hESCs from feeder-free system 
makes the results more accurate due to the exclusion of confounding effects 
caused by feeder cells. 
 Therefore, our study focused on the optimization of autologous 
feeder-dependent hESCs culture systems and the derivation of a xeno-free and 




























Hypotheses and Objectives 
Hypotheses 
 
The main hypothesis is that the derivation of autologous feeder cells from 
hESCs can be optimized and the ECM derived from the autologous feeders 
can further support long-term undifferentiated growth of hESCs in xeno-free, 
serum-free and feeder-free conditions. To support this hypothesis: (a) Stable 
source of autologous feeders should be available from either EB outgrowth or 
hESCs direct differentiation with regards to a better supportive ability for 
long-term undifferentiated growth of hESCs. (b) Human ESCs should be able 
to maintain their undifferentiated growth on ECM substrate derived from 
autologous fibroblast feeders in a xeno-free, serum-free and feeder-free 
condition.  
 
With the aim to verify the above hypotheses, four sequential stages of the 
study were carried out as follows: 
z Stage 1. The derivation of autologous feeder cells was established either 
from outgrowth of 5-day EBs pre-differentiated from H9 hESCs (H9 ebF), 
or from direct differentiation of H9 hESCs (H9 dF). 
z Stage 2. The proliferation capacities, cell origins, expression patterns of 
molecular markers, production of secreted FGF-2 and genomic integrities 
of H9 ebF and H9 dF were characterized and compared accordingly.  
z Stage 3. The supportive abilities of H9 ebF and H9 dF for the long-term 
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growth of H9 hESCs were compared with MEF and MatrigelTM 
extensively. The undifferentiated states, pluripotency, proliferation rates 
and genomic stabilities of H9 hESCs cultured in various systems were 
characterized and compared to identify the optimal autologous feeder for 
long-term culture of hESCs. 
z Stage 4. The ECM was derived from the optimized autologous feeder cells 
and used to support growth of H9 and H1 hESC lines in xeno-free, 
serum-free and feeder-free condition. Comprehensive characterizations 
were carried out to confirm the undifferentiated states and pluripotency of 
both H9 and H1 hESC lines in this system. The possible applications of 




The ultimate aim of this study is to devise an optimal strategy for efficient 
propagation of hESCs in both feeder-dependent and feeder-free systems for 
propagation of clinical-grade hESCs for both basic science studies and clinical 






























Materials and Methods 
3.0 Introduction to materials and methods 
 
This study aims to define optimal autologous systems to support growth of 
hESCs in both feeder-dependent and feeder-free conditions. The derivation of 
autologous feeders, preparations of autologous matrix and characterizations of 
hESCs are crucial to determine the validity of autologous hESC culture 
systems. Therefore, four sequential experiments were carried out to 
differentiate two types of autologous fibroblasts derived from H9 hESCs (3.1) 
and characterize the properties of the autologous cells (3.2). The supportive 
abilities of two autologous feeders were extensively characterized and 
compared with MEF feeder and feeder-free MatrigelTM (3.3). Finally, the ECM 
was extracted from the optimal autologous feeder cells and used to support 
growth of hESCs in xeno-free, serum-free and feeder-free conditions (3.4).  
 
3.1 Derivation of autologous feeder cells (H9-F) from H9 hESCs  
 
In this stage, autologous H9 ebF and H9 dF were differentiated from H9 




Materials and Methods 
3.1.1 Cultivation of H9 hESCs 
   
Cell culture of hESCs was divided into two phases: 1) preparation of MEF, 
2) culture of hESCs.  
 
3.1.1.1. Preparation of MEF 
 
The preparation of MEF includes extraction of embryos from 13.5 days post 
coitum mice, propagation of MEF in culture and mitomycin C inactivation 
before being seeded in gelatin-coated plate to support hESC culture.  
Extraction of embryos: 13.5 days pregnant CF-1 mice were sacrificed by 
CO2 suffocation. The abdomens of mice were disinfected with 70% ethanol 
and the peritoneal walls were cut to expose uterine horns. The uterine horns 
were transferred to petri dish and washed with Ca2+/Mg2+-free phosphate 
buffered saline (PBS, 1st Base) twice before sacs removal and embryos release. 
The number of embryos was counted and the visceral tissues were separated 
from the embryos followed by washing with PBS three times. Excess PBS was 
removed and the prepared embryos were minced by fine iris scissors for 10-15 
minutes for complete dissection. 5ml of 0.05% TE [Trypsin with 
ethylenediaminetetraacetic acid (EDTA), GIBCO, USA] was added to the 
minced embryos and incubated at 37°C for 10 minutes. After vigorous 
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pipetting, 5ml of fresh TE was added to the minced tissue and incubated for 
extra 10 minutes. After TE digestion, 20ml of MEF derivation medium (See 
Table 4 for detailed composition) were used for neutralization. The whole 
sludgy mixture was transferred to 50ml falcon tube and centrifuged at 300×g 
for 5 minutes to remove the supernatant. The tissue mixture was re-suspended 
in fresh MEF derivation medium and plated on 0.1% gelatin (Sigma, USA) 
coated 75cm2 culture flasks at seeding density of 3 embryos per flask. MEF 
were incubated at 37°C in a 5% CO2 atmosphere with 95% humidity. Upon 
90% confluence, the MEF were frozen in MEF freezing media and 
cryopreserved in liquid nitrogen for storage. The composition of freezing 
medium was provided in Table 4. 
Table 4. Compositions of MEF derivation and freezing medium 
MEF derivation Medium (1000ml) 
Dulbecco’s Modified Eagle’s (DMEM) Medium (Sigma) 900ml 
Fetal Bovine Serum (FBS) (Biowest, France) 100ml 
Non-essential amino acids solution (Sigma) 10ml 
Penicillin-Streptomycin 100x solution (GIBCO/Brl) 10ml 
MEF freezing Medium (100ml) 
DMEM Medium 70ml 
Fetal Bovine Serum (FBS) 20ml 
Dimethyl sulfoxide (DMSO) (Sigma) 10ml 
 
Expansion of MEF: The MEF were expanded in MEF derivation medium 
for 3-4 passages, depending on the growth condition, with splitting ratio at 1: 
5. The MEF culture with more than 90% confluence was trypsinized with 
0.05% TE at 37°C for 5 minutes. MEF derivation media were used to 
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neutralize the TE and the cells were transferred to 50ml falcon tube for 
centrifugation at 1200rpm for 8 minutes. The cells pellets were re-suspended 
in fresh MEF derivation medium and re-plate to new culture flask for 
expansion.   
MEF inactivation: The confluent MEF with the desired passage number 
were inactivated by 10μg/ml mitomycin C (Kyowa, USA) dissolved in Hank’s 
balanced salt solution (HBSS, Sigma) for 2 hours. The cells were trypsinized 
by TE at 37°C as described above. The MEF were re-suspended in MEF 
freezing medium and frozen at 1.4 × 106 /ml/vial.  
 
3.1.1.2 Expansion of H9 hESCs  
 
The NIH-registered H9 and H1 hESC lines (Agreement No. 04-W094, 
WiCell Research Institute, Madison, USA) were utilized in this study. The 
hESC culture medium was composed of DMEM/F-12 (GIBCO), 20% 
knockout serum replacement (GIBCO), 4ng/ml basic fibroblast growth factor 
(Invitrogen), 1mM L-glutamine (GIBCO), 1% non-essential amino acid 
(GIBCO) and 0.1mM β-mercaptoethanol (Sigma). When the cells became 
confluent, hESCs colonies were treated with 1mg/ml collagenase IV (GIBCO) 
for 3 minutes at 37°C followed by manual dissection using 5ml serological 
pipettes. The dissected hESCs were transferred to 15ml falcon tube and 
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centrifuged at 200×g for 5 minutes. The cell pellets were re-suspended in fresh 
ES culture medium and seeded on inactivated feeder cells at 1:6 splitting ratio 
every 5-7 days. Originally, hESCs were maintained on inactivated MEF for 
105 passages before transfer to other culture systems. The inactivated feeder 
cells were thawed at 37°C within 2 minutes and plated on 0.1% gelatin 
pre-coated 6-well plate at a density of 1.5 × 105 cell/well one day prior to 
hESC passage. All cells were cultured at 37ºC with 5% CO2 atmosphere and 
95% humidity. 
 
3.1.2. Derivation of autologous fibroblast cells from H9 hESCs 
 
3.1.2.1. Differentiation of H9 ebF from H9 hESCs  
 
Two wells of H9 hESCs were harvested from one 6-well plate after 
collagenase IV treatment. The dissected hESC aggregates were re-suspended 
in EB medium and transferred to two wells of an ultralow attachment 6-well 
plate (NUNC, USA) for cultivation in suspension. The EB medium was 
composed of DMEM/F-12, 20% knockout serum replacement, 1mM 
L-glutamine, 1% non-essential amino acid and 0.1mM β-mercaptoethanol. 
After 5 days in culture, the 2 wells of EB aggregates were seeded on one 0.1% 
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gelatin-coated 75cm2 flask containing fibroblast differentiation media (DMEM 
supplemented with 10% FBS). The cells at this initial passage (P0) were 
maintained in the same flask for 2-3 weeks to allow extensive differentiation, 
after which they were passaged periodically using 0.05% TE until 
morphological homogeneity.  
 
3.1.2.2 Derivation of H9 dF from H9 hESCs  
 
Two wells of H9 hESCs from one 6-well plate were harvested as described 
previously and transferred to 15ml falcon tube for centrifugation at 200×g for 
5 minutes. The H9 hESCs were then re-suspended in 15ml fibroblast 
differentiation medium and plated on one 0.1% gelatin-coated 75cm2 flask for 
adherence culture and differentiation as H9 ebF.  
 
3.2 Characterization and comparison of H9-F 
   
In this stage, the genotypes and phenotypes of H9-F were characterized and 
compared by various assays. The objective was to verify the properties of 
H9-F and to identify the best time point to inactivate H9-F for hESCs culture. 
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3.2.1 Growth curve analysis 
 
The cell proliferation activities of H9 ebF and H9 dF cells were 
characterized from passage 2 (P2) to passage 20 (P20). At the beginning of 
each passage, H9-F were seeded on 25cm2 flasks at a density of 6.7×103 
cells/cm2. The cell number was counted on the third day of every passage.   
 
3.2.2. Identity analysis of H9-F by flow cytometry  
   
The H9-F were stained with fluorescence conjugated mouse MHC class I 
H-2Kd (MHC Id), human CD44 and human prolyl-4 hydroxylase β (P4β) 
antibodies and analyzed by flow cytometry for identification. The detailed 
procedures were described below. 
For the staining of mouse MHC Id marker, approximately 1×106 H9-F at P4 
were prepared in cell suspension and washed once with staining buffer 
comprising 2% bovine serum albumin (BSA, sigma) and PBS. The cells were 
centrifuged at 300×g for 5 minutes at 4°C to remove supernatant, and 
re-suspended in 100μl of staining buffer containing fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse MHC Class I (H-2Kd/H-2Dd) antibody (Santa 
Cruz Biotechnology, USA) diluted at 1:100. The cells were incubated for 30 
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minutes at 4°C followed by twice wash with staining buffer (1 ml/wash for 
staining in tubes). Cells were centrifuged at 300×g for 5 minutes and the 
supernatant was discarded. Finally the cells were re-suspended in 1ml of 
staining buffer and analyzed by flow cytometry. In this experiment, MEF and 
human embryonic palatal mesenchyme cells (CRL1486, ATCC) were served as 
positive control and negative control respectively.  
For the staining of human CD44 antibody, approximately 1×106 of H9-F 
were harvested every 2 passages from P0 to P10 and stained with 
FITC-conjugated anti-human CD44 antibody (eBioscience, USA) as described 
previously.  
For the staining of human fibroblast marker P4β, approximately 1×106 of 
H9-F were harvested by TE treatment every two passages from P0 to P6. The 
cells were re-suspended in 4% paraformaldehyde (Sigma) for 15 minutes at 
room temperature for fixation. After being washed with PBS once, the fixed 
wells were incubated with permeabilization solution (0.2% Tween-20 in PBS) 
at 37°C for 15 minutes followed by centrifugation. The pelleted cells were 
re-suspended in 100μl of staining buffer containing primary mouse anti-human 
P4β (Chemicon, USA) antibody diluted at 1:100. The cells were incubated at 
4°C for 30 minutes. After incubation, 1ml of staining buffer was added and the 
cell suspension was centrifuged (300×g, 5 minutes, 4°C). Supernatant was 
discarded and the wash was repeated once. The cells were re-suspended in 
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100μl staining buffer containing FITC-conjugated rabbit anti-mouse IgG 
(Invitrogen, USA) secondary antibody diluted at 1:100 and incubated for 15 
minutes at 4°C in the dark. The cells were washed twice as described above and 
re-suspended in 1ml of 1% paraformaldehyde (Sigma) and stored at 4°C for 
flow cytometry analysis. 
The flow cytometry analysis was carried out by Dako Cytomation Cyan LX 
(Dako Cytomation, Denmark) and the results were analyzed by Summit v4.3 
software (Beckman Coulter, USA).  
 
3.2.3. Gene expression analysis by reverse transcription-polymerase chain 
reaction (RT-PCR)  
 
The gene expression patterns of H9-F were characterized by conventional 
RT-PCR. The cells of H9-F were harvested at every passage numbers from P0 
to P9. The cells were spun down at 300×g for 5 minutes to remove residual 
medium, followed by twice washes with PBS. The pelleted cells were 
subjected to RNA extraction using RNeasy Mini Kit (QIAGEN, USA), 
following the manufacturer’s instructions. The concentrations of RNA were 
determined by Nanodrop ND-1000 spectrophotometer (Nanodrop technologies, 
USA). For cDNA synthesis, 500ng of total mRNA per 20μl reaction volume of 
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each sample was transcribed into cDNA reversely using iScript cDNA 
synthesis Kit (Bio-Rad, USA). The reaction mixture contained 4μl of 5×cDNA 
synthesis kit buffer, 1μl of iScript enzyme mixture, 500ng of mRNA samples 
and RNase-free water. The cDNA synthesis was carried out in thermal cycler 
(MycyclerTM BioRad) with the following protocol: 5 min at 25°C, 30 min at 
42°C, 5 min at 85°C and held at 4°C. The obtained cDNA samples were 
subjected to PCR amplifications for 35 cycles (Denaturing: 95°C, 30 seconds; 
Annealing: as described in table 5, 45 seconds; Extension: 72°C, 60 seconds) 
followed by extra extension at 72°C for 10 minutes and held at 4°C in 
MycyclerTM. The components of the PCR reaction mixture were listed in Table 
5. The amplified genes and the corresponding primers were listed in Table 6. 
The expression of house-keeping gene β-actin were served as internal 
standard.  
 
Table 5. Components of PCR reaction mixtures 
Components Volume 
(μl) Concentration 
5X Green GoTaq® Flexi Buffer (Promega, USA) 4 1X 
GoTaq® Flexi DNA Polymerase (Promega) 0.1 1.25u 
25mM MgCl2 (Promega) 1.2 1.5mM 
Forward primer (1st base, Singapore) 0.4 0.2µM 
Reverse primer (1st base) 0.4 0.2 µM 
dNTP (Promega) 0.4 0.2mM each dNTP 
cDNA template 1 <0.01µg/µl 
Distilled and deionized H2O (ddH2O) 12.5 N.A 
Total volume 20 N.A 
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Table 6. List of Primers 
Genes 






















































F: ACTGGTGTCTCTGTGCTTCCTT          








The amplified PCR products were loaded onto 2% agarose gel and 
subjected to electrophoresis for 35 minutes under 65 voltages. The DNA bands 
were visualized by Ultraviolet (UV) illumination and the images were 
captured by Universal hood II (BioRad).  
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3.2.4. Evaluation of FGF-2 secretion in H9-F conditioned medium by 
enzyme-linked immunosorbent assay (ELISA) 
 
From P2, autologous H9-F were continuously split until 20 passages. Cells 
were seeded at a density of 2×104cells/cm2 in two 25cm2 flasks containing 
fibroblast differentiation medium. Cells in one flask were allowed to get 
confluent before inactivation by inactivation solution (10μg/ml mitomycin C 
in HBSS) for 2 hours. After the treatment, the inactivation solutions were 
removed from the flasks. The adherent cells were washed with PBS twice and 
then incubated with 5ml of fresh fibroblast differentiation media. The media 
conditioned by inactivated H9-F were collected 5 days after incubation, 
transferred to 15ml falcon tubes, lyophilized overnight at -80°C and frozen at 
-20°C before analysis. The adherent inactivated cells were trypsinized as 
described before, centrifuged at 300×g for 5 minutes and frozen at -20°C. The 
cells in a parallel flask were allowed to grow confluent and then split into two 
25cm2 flasks with the same seeding density of 2×104cells/cm2. For ELISA 
analysis, the lyophilized conditioned media were dissolved in 1ml of PBS and 
the human bFGF level in the concentrated conditioned media were quantified 
by Quantikine Immunoassay kit (R&D Systems, USA), following 
manufacturer’s instructions. The corresponding cell pellets were lyzed in 0.5% 
sodium dodecyl sulfate (SDS) with vigorous vortex and the total protein exact 
was assayed by DC protein assay kit (Bio-Rad). The bFGF level was adjusted 
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to the total protein extract with the below formula:  
Normalized level of bFGF = concentration of bFGF/ concentration of total 
protein extract 
 
3.3. Characterization and comparison of H9 hESCs cultured on 
autologous H9-F, MEF and feeder-free MatrigelTM 
 
In this stage, inactivated H9-F and MEF were used to support 
feeder-dependent culture of H9 hESCs while commercially-available 
MatrigelTM was used to support H9 hESCs in a feeder-free condition. Various 
assays were employed to quantify the undifferentiated states and 
differentiation potentials of H9 hESCs supported by H9-F, MEF and 
MatrigelTM respectively. The objective was to characterize and to compare the 
supportive abilities of two autologous feeders, MEF and MatrigelTM.  
 
3.3.1. Cultivation of H9 hESCs in various culture systems.  
 
More than 60 passages of H9 hESCs were cultured on inactivated H9 dF, 
H9 ebF and MEF in feeder-dependent conditions. In addition, MatrigelTM was 
used in couple with mTeSRTM1 medium (Stemcell Technologies, Canada) to 
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support feeder-free culture of hESCs for 22 passages. Autologous H9-F were 
inactivated by 10µg/ml mitomycin C at the desired passage number and plated 
on gelatin-coated 6-well pates at a seeding density of 1.87×105/well 1 day 
prior to hESCs seeding (Fu et al., 2009). The culture medium and splitting 
procedure were the same as described in 3.1.1.  
For the feeder-free system, one aliquot (varies between 70μl to 80μl from 
batch to batch) of frozen BD MaterigelTM hESC-qualified matrix (BD 
Biosciences, USA) was thawed at 4°C overnight and diluted in 6ml of cold 
DMEM-F12. The diluted matrix solution was immediately used to coat one 
6-well plate at 1ml/well at room temperature for at least one hour before use. 
After coating, excess liquid was removed and 1.5ml of fresh mTeSRTM1 
medium, containing mTeSRTM1 basal medium and 1× supplementary serum 
(StemCell Technologies), was added into each one well of a 6-well plate 
before seeding hESCs. The hESCs were allowed to reach 90% confluency 
before passage. For splitting, the hESCs were treated with 1ml of 1mg/ml 
dispase (BD Biosciences) per one well of a 6-well plate for less than 3 minutes. 
The dispase was removed and the cells were rinsed with DMEM-F12 once. 
After wash, 2ml/well of mTeSRTM1 media were added into the plate and 5ml 
serological pipette was used to manually dissect and scrape the cell colonies 
from the plate. The cells were centrifuged at 200×g for 5 minutes and the 
supernatant were discarded. The cells were re-suspended in fresh mTeSRTM1 
media and seeded on the freshly prepared MatrigelTM-coated plate at the 
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splitting ratio of 1:6. H9 hESCs were split every 4-5 days depending on the 
culture condition.  
All cells were cultured at 37ºC with 5% CO2 atmosphere and 95% humidity. 
The morphologies of hESCs in each culture system were subjected to 
microscopy examination at every passage.  
 
3.3.2 Cryopreservation assay 
 
To study the recovery abilities of cryopreserved H9 hESCs on autologous 
feeders, the conventional cryopreservation technique was applied to hESCs 
after propagation on autologous feeders for 7 passages. The procedures below 
provide details: The hESCs were allowed to grow confluency before passage. 
The dissected cells were transferred to 15ml falcon tubes and centrifuged at 
200×g for 5 minutes. The supernatant were discarded and the cells were 
re-suspended in ES freezing medium composed of 60% ES medium, 10% 
DMSO (Sigma) and 30% defined serum (Invitrogen, USA). H9 hESCs from 
one well of a 6-well plate were transferred to 2 vials of cryovials (NUNC) at 
1ml/vial and frozen in freezing container (Nalgene, USA) at -80 ºC overnight 
prior to cryopreservation in liquid nitrogen. One week after freezing, one 
cryovial of cells were thawed at 37 ºC, transferred to a 15ml falcon tube, 
diluted with 9ml of ES media and centrifuged at 200×g for 5 minutes. The cell 
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pellet was re-suspended in fresh ES medium and then seeded on newly 
prepared feeders. The cryopreservation assay was also applied to the MEF 
system and the feeder-free MatrigelTM system as controls. The passage 
numbers of H9 hESCs before and after cryopreservation assay were 
summarized in Table 7.  
 
Table 7. Cryopreservation of H9 hESCs from various culture systems 







Passage number cultured on 
MEF 105 105 105 120 
Number of passages cultured on 
various feeders before freezing 7 7 7 17 
Number of passages cultured on 
various feeders after thawing 53 53 53 5 
Total passage number (number 
of passages cultured on 
autologous feeder) 
165(60) 165(60) 165(60) 142 (22) 
 
3.3.3. Immunofluorescence staining 
 
After propagation on autologous feeders and MatrigelTM for 22 passages, 
the undifferentiated states of H9 hESCs were assessed by immunofluorescence 
staining for hESC-specific markers: Oct4, SSEA-4 and Tra-1-60. Briefly, the 
H9 hESCs cultured in a 24-well plate were washed with PBS once before 
fixation with 4% paraformaldehyde at room temperature for 15 minutes. The 
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samples were washed twice with PBS for 5 minutes, permeabilized with 0.2% 
Triton X-100/PBS for 10 minutes and blocked with PBS containing 5% 
normal goat serum (Vector Laboratories, USA) and 2% BSA (Sigma) for 1 
hour at room temperature. The cells were incubated with rabbit anti-human 
Oct4 antibody (Santa Cruz Biotechnology) diluted at 1:200 in staining buffer 
(2% BSA in PBS) at 4ºC overnight. Isotype control IgG1 antibody (Santa Cruz 
Biotechnology) was incubated in the same conditions. After overnight 
incubation, the cells were washed with washing buffer (PBS/0.05% Tween20) 
for 5 minutes twice, PBS for 5 minutes once, and then incubated with Alexa 
Fluor 594 conjugated goat anti-rabbit IgG secondary antibody (Invitrogen) 
diluted at 1:200 in staining buffer for 2 hours at room temperature in darkness. 
The cells were washed with washing buffer for 5 minutes twice, PBS for 5 
minutes once, and then mounted with slow fade gold antifade reagent 
containing Dapi (Invitrogen) to localize the nucleus. Immunofluorescence 
staining for SSEA-4 and Tra-1-60 were carried out using mouse anti-human 
SSEA-4 antibody (Chemicon) and mouse anti-human Tra-1-60 antibody 
(Chemicon) respectively. Alexa Fluor 488 conjugated goat anti-mouse IgG 
secondary antibody (Invitrogen) was used to detect the existence of primary 
antibodies. The same staining procedures were performed as described 
previously but excluded permeabilization step. All the staining results were 
examined under Olympus IX70 fluorescence microscope. 
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3.3.4. Alkaline phosphatase (ALP) staining 
  
  After propagation in various systems for 22 passages, the H9 hESCs were 
stained for ALP activities using ALP kit (Sigma), following manufacturer’s 
instructions. Briefly, the H9 colonies were fixed in citrate buffered acetone for 
30 seconds, rinsed in ultrapure water (Milli-Q® Ultrapure Water Purification 
Systems, Millipore, USA) for 45 seconds, and stained with alkaline-dye 
mixture for 30 minutes in darkness before examination. An inverted 
microscope with MicroimageTM software (Olympus, Japan) was used to 
capture digital images.  
 
3.3.5. Proliferation analysis  
 
Proliferation activities of hESCs were analyzed by two assays: cell 
cycle/DNA profile analysis by propidium iodide (PI) staining and Vybrant 
5-(and-6)-carboxyfluorescein diacetate-succinimidyl ester (CFDA-SE) cell 
tracer labelling. 
Cell cycle/DNA profile analysis: The percentage of cells in S and G2/M 
phase reflected the proliferation activities of the cells. The cell cycle/DNA 
profiles in H9 hESCs were detected by staining DNA contents with PI. In 
detail, H9 hESCs that had been expanded in culture for 44 passages were 
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harvested from one 6-well plate on day 4 of culture, corresponding to the 
maximal growth rate (Fluckiger et al., 2006; Fu et al., 2009). The cells were 
washed with PBS once and then dissociated into single cells at 37°C for 5 
minutes with dissociation solution containing TE and cell dissociation buffer 
(GIBCO) at the ratio of 7:3 in volume. The dissociated cells were passed 
through pre-rinsed 60μm filters to remove any cell clusters, centrifuged to 
remove supernatant, re-suspended in 1ml of 0.25% paraformaldehyde and 
fixed at 4°C for 1 hour. After incubation, 1ml of cold PBS was added and cells 
were spun down at 300×g for 5 minutes at 4°C. Supernatant was removed by 
aspiration and 1ml of permeabilization solution (0.2% Tween 20 in PBS) was 
added. The cells were mixed gently and incubated at 37°C for 15 minutes. 
After permeabilization, 1ml of PBS was added and the cells were centrifuged 
at 300 × g for 5 minutes at 4°C. The supernatant was replaced with 1ml of PI 
staining solution [PBS containing 0.1% (v/v) Triton X-100, 100μg/ml of PI 
(Sigma) and 100μg/ml Ribonuclease A (MP Biomedicals)] to resuspend the 
cell pellet. The PI-stained samples were protected from light and analyzed by 
Dako cytomation Cyan LX within 1 hour after staining.  
CFDA-SE cell tracer labeling: the proliferation activities of H9 hESCs 
were measured by CFDA-SE staining using Vybrant CFDA-SE cell tracer kit 
(Invitrogen), following manufacturer’s instructions. In detail, the confluent H9 
hESCs that had been expanded in culture for 50 passages were incubated with 
pre-warmed PBS containing 8μM/ml CFDA-SE at 37°C for 15 minutes. The 
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solution was replaced with fresh, pre-warmed ES media and incubated for 
another 30min. The hESCs were detached by collagenase IV digestion as 
adopted for routine hESC splitting. The obtained cell clumps were separated 
into two portions, one for fixation and the other for subsequent passage. For 
fixation, the cells must be washed with PBS once before centrifugation. The 
cells were dissociated into single cells and fixed with 100ul of 3.7% 
formaldehyde for 20 minutes on ice. The tube containing fixed cells were 
filled to the top with PBS containing 1% BSA (Sigma) and stored at 4°C until 
analysis. The hESC samples were collected on day 3 and day 5 after passage 
as well as were fixed as described previously. The fluorescence intensities of 
CFDA-SE labeling in hESCs at different time points were detected by Dako 
cytomation Cyan LX 
 
3.3.6. Pluripotency analysis by EB formation and teratoma formation 
 
The pluripotency of H9 hESCs propagated on autologous feeders was 
characterized by in vitro EB formation and in vivo teratoma formation. 
EB formation:  The H9 hESCs were allowed to propagate in various 
culture systems for 20 passages before EB formation assay. The confluent 
hESCs were detached from the plate and centrifuge to discard supernatant. 
The cell pellet was resuspended in the EB medium and cultured in suspension 
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in an ultra low-attachment 6-well plate for 21 days with medium change every 
alternative day. The EB samples were collected after 5 days (5D), 7 days (7D), 
14 days (14D) and 21 days (21D) respectively. The EB samples were further 
subjected to real time PCR analysis, which will be described in 3.3.7.  
Teratoma formation: After cultivation on autologous feeders for 60 
passages, H9 hESCs were injected into 5-week old SCID mice to induce 
teratoma formation. H9 hESCs from the MEF feeder system with the same 
passage number were used as a positive control. To assess the tumorigenicity 
of H9-F, both H9 ebF and H9 dF were administrated into SCID at P6 by 
intramuscular injection respectively. Approximately 3×106 of hESCs and H9-F 
were injected into the thigh muscle of SCID mice. Mice were sacrificed 6-11 
weeks post-injection to collect teratoma clumps if any. One mouse was used 
for the injection of hESCs from each culture system. The teratoma samples 
were processed by hemotoxylin and eosin staining (H&E staining) as 
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3.3.7. Undifferentiated states analysis of H9 hESCs cultured in various 
systems.  
 
3.3.7.1. Immunofluorescence staining and flow cytometry analysis for Oct4 
and SSEA-3/4 expression in hESCs 
   
To quantify undifferentiated states of hESCs, the percentage of Oct4 
positive and SSEA-3/4 positive cells cultured on autologous feeders were 
analyzed by flow cytometry at P40. For Oct4 staining, H9 hESCs were 
scraped down after the collagenase IV treatment, dissociated into single cells, 
fixed with 0.25% paraformaldehyde for 1 hour at 4°C and permeabilized in 
PBS containing 0.2% Tween-20 at 37°C for 15 minutes. After being washed 
with PBS once, the cell pellet was resuspended in 100μl staining buffer (2% 
BSA in PBS) containing rabbit anti-human Oct4 antibody (Santa Cruz 
Biotechnology, diluted at 1:100). The cells were incubated at 4°C for 30 
minutes. After incubation, 1ml of staining buffer was added and the cell 
suspension was centrifuged (300×g, 5 minutes, 4°C). Supernatant was 
discarded and the wash was repeated once. The cell pellets were then 
resuspended in 100μl staining buffer containing Alexa Fluor 594 conjugated 
goat anti-rabbit IgG secondary antibody (Invitrogen, diluted at 1:100) and 
incubated for 15 minutes at 4°C in the darkness. The cells were washed twice 
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and resuspended in 1ml of 1% paraformaldehyde for fixation. The samples 
could be stored at 4°C for a few days before flow cytometry analysis. The 
same procedure was applied to the immunofluorescence staining of SSEA-3/4 
using mouse anti-human SSEA-3/4 primary antibody (Chemicon) and Alexa 
Fluor 488 conjugated goat anti-mouse IgG secondary antibody (Invitrogen). 
The percentage of hESCs expressing Oct4 and SSEA-3/4 were analyzed by 
Dako cytomation Cyan LX.  
 
3.3.7.2. Conventional RT-PCR and real-time RT-PCR 
  
  The expression of hESC-specific markers (Oct4, Nanog, Sox2) and three 
germ layers markers (NeuroD1, Brachyury, AFP) were analyzed in H9 hESCs 
from P1 until P20 by semi-quantitative RT-PCR. The RT-PCR analysis of 
hESCs was carried out following the same procedures as described in 3.2.3. To 
further quantify the undifferentiated states of hESCs in different systems, the 
expression of hESC-specific markers were subjected to quantitative real-time 
RT-PCR at P1, P10 and P20 by using Fast SYBR® Green master mix system 
(Applied Biosystems, USA). To quantify the degree of spontaneous 
differentiation in routine hESC culture, the expressions of NeuroD1, 
Brachyury and AFP were evaluated by real-time RT-PCR at every five 
passages from P1 to P20. The real-time RT-PCR was performed on Applied 
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Biosciences 7500 fast real time PCR system (Applied Biosystems) The 
primers used were summarized in Table 8. The level of expression of each 
target gene was then calculated as 2-∆∆Ct as described previously (Livak KJ et 
al., 2001). Each sample was repeated three times for each gene of interest. 
 
Table 8. Primers used in RT-PCR and real-time RT-PCR analysis for hESCs 
Genes 
































The differentiation potentials of hESCs culture in various systems were 
evaluated by expression patterns of EB samples using RT-PCR and real-time 
PCR. EB samples collected in 3.3.6 were subjected to conventional RT-PCR. 
The 21D EB samples were further analyzed by real-time PCR. The primers 
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Table 9. Primers used in conventional and real-time RT-PCR for EB samples 
Genes 





















F: CCCGAACTTTCCAAGCCATA     













3.3.8. Karyotype analysis 
 
  Autologous H9-F and H9 hESCs were subjected to karyotype analysis at P6 
and P30 respectively. Cells were blocked in metaphase by using 7ng/ml 
colcemid at 37ºC for 8 hours. The treated cells were harvested and transferred 
to 15ml falcon tubes for centrifugation. The supernatant was carefully 
removed, leaving approximate 0.3ml medium in the tube. Then 5ml of 
pre-warmed hypertonic 75mM KCl solution was added in cell suspension 
slowly. The resuspended cells were incubated for 20 minutes at 37ºC, 
centrifuged to decant supernatant and fixed by adding 5ml of cold (4ºC ) 
methanol and acetic acid (3:1, v/v) dropwise. The fixative treatment was 
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repeated 2 to 3 times to exclude water residual in the cell suspension. After 
sufficient fixative treatment, few spots of cells were dropped on a pre-cleaned 
(ether/ethanol 1:1) slide to make metaphase spread. The slides were air-dried 
over night at 65°C before hybridization. Multi-color fluorescence in situ 
hybridization (mFISH) analysis was performed using Metasystems 24XCyte 
multicolor mFISH probe kit (Metasystems, Germany). Finally, slides were 
analyzed with a Zeiss Axioplan microscope (Carl Zeiss GmbH, Germany) 
equipped with a cooled charged device (CCD) camera (Sensicam, Germany). 
ISIS FISH imaging software (Metasystems) were used for capturing 
fluorescent images.  
 
3.4. Cultivation of hESCs on H9 ebF-derived ECM in xeno-free, 
serum-free and feeder-free conditions 
 
3.4.1. Extraction of ECM from H9 ebF 
 
H9 ebF were seeded at a density of 2.5×105/well on a 6-well plate 
pre-coated with 6μg/cm2 human collagen IV (Sigma) and allowed to attach 
overnight in DMEM+10% FBS medium. On the next day, the media were 
replaced with ECM-deposition medium, containing DMEM with 0.5% FBS, 
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50µg/ml Ascorbic Acid (Sigma) and 100 µg/ml of dextran sulfate (Sigma). 
Cells were cultured at 37°C for 3 days to allow the build-up of ECM on the 
plate. Plates were frozen with media at -80°C overnight and thawed at room 
temperature. Then the medium was removed. Plates were rinsed with PBS 
three times to remove cell debris followed by air-drying in the lamina flow 
cabinet. The prepared plated could be sealed with parafilm and stored at -20°C 
for long-term storage.  
 
3.4.2. Characterization of ECM by fluorescence confocal microscopy 
 
The ECM was fixed on the non-coated 4-well coverglass chambers (lab-Tek) 
with 4% paraformaldehyde and stained with antibodies following the 
procedures described in 3.3.3. The primary antibodies included mouse 
anti-human collagen IV antibody (Sigma), mouse anti-human collagen I 
antibody (Santa Cruz biotechnology), mouse anti-human collagen VI antibody 
(Chemicon), rabbit anti-human fibronectin antibody (Chemicon), and rabbit 
anti-human laminin antibody (Chemicon). The secondary antibodies were 
Alexa Fluor 488 conjugated goat anti-mouse IgG (Invitrogen) and Alexa Fluor 
594 conjugated goat anti-rabbit IgG (Invitrogen) antibodies. The dilution 
factor for antibodies preparation was 1:200. The chambers were examined 
under confocal microscope (Olympus Fluoview FV1000, Japan). The digital 
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images were captured and analyzed using FV10-ASW 2.0 Viewer software 
(Olympus, Japan). The 3-D images were constructed using Imaris 3D 
interactive image visualization software (Bitplane Scientific Software, 
Switzerland).      
 
3.4.3. Cultivation of H9 and H1 hESC lines on ECM in xeno-free, serum-free 
and feeder-free conditions 
 
3.4.3.1. Expansion of hESCs 
   
H9 hESCs and H1 hESCs were continuously cultured on MEF for 56 
passages and 50 passages respectively before transferring to feeder-free 
culture systems. The feeder-free culture systems were maintained in 
commercial animal-component free medium TeSRTM2 (StemCell Technology). 
The splitting method for ECM-supported hESC culture system was described 
as below: The hESCs were allowed to grow confluent on ECM and were 
detached with 1mg/ml collagenase at 37°C for 5 minutes. The enzyme solution 
was then replaced with 2ml of TeSRTM2. The cells were manually scraped 
down from the plate using 5ml serological pipette followed by centrifugation 
to remove supernatant. The pelleted cells were resuspended in TeSRTM2 media 
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and seeded on newly prepared ECM-coated plates at splitting ratio of 1:3. 
Cells were split every 4 days.  
 
3.4.3.2. Characterization of hESCs by immunofluorescence staining and flow 
cytometry 
 
  Being cultured on ECM for 10 passages, both H1 and H9 hESCs were 
subjected to immunofluorescence staining with antibodies specific to human 
Oct4, SSEA-3/4 and Tra1-60. The staining protocol was the same as described 
in 3.3.3. The percentages of Oct4 and SSEA-3/4 positive cells were further 
evaluated by flow cytometry following the same procedures as described in 
3.3.7.1.  
 
3.4.3.2. Proliferation analysis  
 
  The proliferation activities of hESCs were characterized by cell cycle/DNA 
content analysis using PI staining followed by flow cytometry analysis. The 
hESCs on day 3 were harvested, stained with PI staining solution and analyzed 
by flow cytometry as described in 3.3.5.   
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3.4.3.3. Pluripotency analysis by EB formation and teratoma formation 
 
  The differentiation potentials of ECM supported hESCs were induced to 
form EB after propagation on ECM for 10 passages. The hESCs with the same 
passage number were injected into SCID mice for teratoma formation. Tumor 
clumps were harvested at week 9 and processed with H&E staining.  
 
3.4.3.4. Undifferentiated state analysis by RT-PCR and real-time RT-PCR 
 
  The expression of hESC-specific markers (Oct4, Nanog and Sox2) and 
three-germ layer markers (NeuroD1, Brachyury and AFP) were analyzed in 
ECM-supported hESCs at P10 and P20 by RT-PCR and at P20 by real-time 
RT-PCR. The expression patterns of EB samples (5D, 14D and 21D) from the 
ECM culture system were analyzed using primers specific to neuroD1, NF-68, 
Brachyury, PPAR-γ, AFP and α1-AT. The detailed procedures were the same 
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3.4.4. Application of ECM-supported hESCs 
 
3.4.4.1. In vitro osteogenic differentiation of ECM-supported hESCs 
 
ECM-supported hESCs (H1 and H9) were seeded on 0.1% gelatin-coated 
plates at a seeding density of 2.5×104cells/cm2 and induced by osteogenic 
differentiation medium with compositions as shown in Table 10. The media 
were changed every three days and the differentiated cells were stained with 
Alizarin Red on day 21 for mineralization assay. The staining procedures were 
described as below (Osyczka et al., 2002). 
 
Table 10. Composition of osteogenic differentiation medium 
 
Chemicals  Working concentration  
DMEM 90% 
FBS 10% 
Dexamethasone 10-7 M 
Ascorbate-2-phosphate 2×10-4 M 





The cells were washed with PBS once and fixed with 10% formalin for 30 
minutes at room temperature, followed by washing three times with PBS. The 
cells were then stained with 2% Alizarin red S solution (Sigma, pH4.1-4.3) for 
30 seconds. The staining solution was removed and the cells were washed 
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with water with gentle agitation until non-specific staining was completely 
removed. The plate air-dried and was examined under microscope. 
 
3.4.4.2. Cytotoxicity testing of NaF on ECM-supported H9 hESCs, H9 ebF 
and CRL1486 by MTS assay 
 
H9 hESCs were seeded on ECM-coated 96-well plates at a seeding density 
of 1.25x103/cm2. H9 ebF (P7) and CRL1486 (P11) were seeded at the same 
seeding density (1.25x103/cm2) on 96-well plates as well. For each culture 
system, cells were treated with 4 different concentrations of NaF solutions 
(2mM, 4mM, 8mM and 12mM) for both 2 hours and 24 hours respectively. 
Experiments were run in quadruplicate. The MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) assay was applied after the treatment and the mitochondrial 
activities of cells after the treatment were evaluated by a plate reader at the 
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3.5 Statistical Analysis 
   
Statistical analysis was performed using the SPSS statistical package. 
Difference was evaluated by Student’s t-test and one way ANOVA test. A 

























4.1. Derivation of autologous fibroblast cells from H9 hESCs 
 
4.1.1. Morphology of H9 ebF  
 
After 5-day suspension, H9 hESCs formed sphere-shaped EB aggregates 
(Figure 2A). The EB aggregates adhered to the gelatin-coated flask 24 hours 
after plating. Fibroblast-like cells were observed to proliferate and migrate 
outwards from EB aggregates within 24-48 hours of attachment (Figure 2B). 
The outgrowing cells proliferated gradually and reached confluency after 2-3 
weeks of culture. These cells were heterogeneous and composed of different 
progenitors with different morphologies (Figure 2C). After 2 passages, cells 
became spindle-shaped and morphologically homogeneous (Figure 2D).  
 
4.1.2. Morphology of H9 dF  
 
H9 hESC clumps attached to the gelatin-coated plate within 24 hours after 
seeding. Fibroblast-like cells were firstly observed within 48 hours of 
attachment (Figure 3A). These cells were highly expandable (Figure 3B) and 
reached confluency after 2-3 weeks in heterogeneous morphology (Figure 3C). 

















Figure 2. Derivation of H9 ebF. H9 ebF were derived from 5-day EB 
aggregates differentiated from H9 hESCs. (A). Formation of EB aggregates 
after 5-day in suspension. (B). Spindle-shaped fibroblastic cells were 
outgrowing from the peripheral of adherent EB aggregates. (C). 
Outgrowing cells were confluent after 2-3 weeks with heterogeneous 
morphologies. (D). Homogeneous cells with spindle shape appeared after 
successive two passages. 
  
 

























Figure 3. Derivation of H9 dF. H9 dF were differentiated directly from H9 
hESCs. (A). Dissected ES colonies were attached to the gelatin-coated plate 
within 24 hours after plating. (B). Cells were differentiated in monolayer 
with various morphologies. (C). H9 dF were proliferated extensive for 2-3 
weeks and became confluent with heterogeneous morphologies. (D). H9 dF 












4.2. Characterization and comparison of H9 ebF and H9 dF 
 
4.2.1. Growth kinetics 
 
The proliferation ability of H9 ebF and H9 dF were analyzed every passage 
between P2 and P20. Both cells proliferated rapidly for up to 20 passages. 
Their growth curves are shown in Figure 4. The numbers of cells at every 
passage are summarized in Appendix. Particularly, H9 ebF displayed higher 
proliferation rates than H9 dF from P11 onwards.  
 






















Figure 4. Growth kinetics of H9 ebF and H9 dF from P2 to P20. Cells were 
highly expandable up to passage 20. Particularly, H9 ebF displayed higher 









To exclude the possible contamination of MEF in the autologous H9-F, the 
mouse cells were analyzed by the measurement of the percentages of cells 
expressing mouse MHC class 1 H-2Kd (MHC Id) antigen. The MEF were 
derived from CF-1 mice whose H-2 haplotype has been identified to be MHC 
Id (Lin et al., 2005). Therefore, the percentage of MHC Id-positive cells in 
H9-F would suggest the magnitude of contaminated MEF. In this testing, the 
pure MEF were employed as a positive control, while the immortalized human 
palate mesenchymal cell line (CRL1486) served as a negative control. By P4, 
99.21% of H9 ebF and 99.96% of H9 dF were stained negatively by mouse 
MHC-Id antibody, suggesting the depletion of contaminant MEF in autologous 




























Figure 5. Flow cytometric analysis of H9-F cell surface expression of 
mouse MHC Id marker. By P4, 99.21% of H9 ebF and 99.96% of H9 dF 
were stained negatively by mouse MHC Id antibody. The pure MEF derived 
from CF-1 mouse were employed as a positive control while human palate 
mesenchymal cell line (CRL1486) served as a negative control. Neg Ctrl 










It has been reported that the cell surface marker CD44 is not present in 
undifferentiated hESCs but in committed cell lineages (Haegel et al., 1994). 
Therefore, the differentiation progress of H9 ebF and H9 dF were quantified 
by measuring the percentage of CD44 positive cells from P0 to P10 in every 
other passage numbers. The percentages of CD44 positive cells gradually 
increased along the extended culture (Figure 6). By P6, 99.02% of H9 ebF and 
99.66% of H9 dF expressed CD44, suggesting a majority of cells were 






























Figure 6. Flow cytometric analysis of H9-F cell surface expression of 
CD44 marker. Histograms of H9 ebF and H9 dF expressing CD44 markers 
were generated by flow cytometric analysis. The percentages of CD44 
positive H9-F increased gradually along the extended culture. More than 
99% of H9 ebF and H9 dF expressed CD44 after in vitro expansion for 6 








To further verify the identities of H9 ebF and H9 dF, they were 
characterized by the expression of fibroblast marker prolyl-4 hydroxylase β 
(P4β). Figure 7 demonstrated strong positive fluorescence signals of P4β 
detected on H9 ebF and H9 dF. Then the percentages of fibroblast cells in 
H9-F cell populations were further evaluated by flow cytometry. The results 
demonstrated that from P6 onwards, more than 99% of both H9-F were 
stained by P4β antibody (Figure 8).  
 








Figure 7. Immunofluorescence staining of H9-F for expression of fibroblast 
marker P4β. At P6, fibroblastic identities of H9 ebF and H9 dF were 
confirmed by immunofluorescence staining for intracellular fibroblast 




































 Figure 8. Quantification of purity of fibroblastic H9-F by flow cytometric 
analysis. The percentages of H9 ebF and H9 dF expressing intracellular 
fibroblast marker P4β were gradually increased. At P6, more than 99% of 
H9 ebF and H9 dF were stained by P4β antibody. P4β stands for prolyl-4 









To further characterize the identities of H9 ebF and H9 dF, their gene 
expression profiles were investigated by RT-PCR (Figure 9) from P0 to P9. 
For hESC specific markers, gradual declining expressions of Oct4 and Nanog 
were detected in H9 dF, and the complete disappearance of Oct4 and Nanog 
expressions were observed at P1 and P5 respectively. However, both of the 
genes had not been detected in H9 ebF since P1.  
Then the expressions of three germ layer markers on H9 ebF and H9 dF 
were studied. The ectoderm markers are NeuroD1 and NF68, the mesoderm 
markers are Brachyury and PPAR-γ, and the endoderm markers are AFP and 
α1-AT. Results showed that the expressions of NF68 and α1-AT were detected 
in both H9 ebF and H9 dF at early passage numbers. Continuous expression of 
PPAR-γ could be observed in H9 ebF and H9 dF until P9. In contrast, the 
expressions of Brachyury, AFP and NeuroD1 markers were not present in both 
cells.  
In addition, fibroblast specific markers, Vimentin and P4β, were found to be 
strongly expressed in autologous H9-F; whereas the expression of epithelium 
marker, cytokeratin 4, was not detectable over the period of 10 passages in 
neither H9 ebF nor H9 dF, suggesting the fibroblast-like characteristics of 




Figure 9. Gene expression profiles of H9 ebF and H9 dF by conventional 
RT-PCR. H9 ebF depleted hESC markers Oct4 and Nanog since P1. However, 
gradual declining expressions of hESC markers were detected in H9 dF. The 
complete disappearance of Oct4 and Nanog expressions were observed at P1 
and P5 respectively. Three germ layer markers were not expressed in H9-F 
since P6 except mesoderm marker PPAR-γ, which was expressed persistently 
up to P9. Two fibroblast markers, Vimentin and P4β, were strongly expressed 
in autologous H9-F, whereas the expression of epithelium marker, cytokeratin 
4, was not detectable over the period of 10 passages in neither H9 ebF nor H9 
dF. The critical component of hESC culture medium, FGF-2, was expressed in 
both H9 ebF and H9 dF over the period of 10 passages at mRNA level. 
Ectoderm markers: NeuroD1, NF-68. Mesoderm markers: Brachyury (Bra), 
PPAR-γ. Endoderm markers: α1-AT, AFP. Epithelium marker: Cytokeratin-4 










4.2.5. Synthesis and secretion of FGF-2 
 
Because FGF-2 is one of the critical components of hESC culture medium to 
maintain the undifferentiated status and support the growth of hESCs, its 
synthesis and secretion by H9 ebF and H9 dF were analyzed by conventional 
RT-PCR and ELISA respectively. At mRNA level, FGF-2 was continuously 
transcripted in both H9 ebF and H9 dF from P0 to P10. In comparison with H9 
ebF, H9 dF had less transcription of FGF-2 (Figure 9). In the conditioned 
media of H9-F, the concentrations of secreted FGF-2 increased from P5 
onwards and maintained at high levels with fluctuation (Figure 10). The 
reading is summarized in Appendix. From P4 onwards, H9 ebF cells were 


















































Figure 10. ELISA analysis of H9-F conditioned medium for concentration of 
FGF-2. In the H9-F conditioned media, the normalized concentrations of 
secreted FGF-2 increased from P5 onwards and maintained at high levels with 
fluctuation. From P4 onwards, H9 ebF were capable of secreting significantly 
















A normal diploid karyotype of 44,XX was confirmed in both H9 ebF and 
H9 dF by mFISH at P6, suggesting the genetic integrities of autologous H9-F 
after long-term cultivation. The metaphase spread and karyograms are shown 
in Figure 11. 
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Figure 11. Karyotypes of autologous H9-F. The genomic integrities of H9 
ebF and H9 dF were characterized by multi-color in situ hybridization 
(mFISH). A normal diploid karyotype of 44,XX was confirmed in both H9 
ebF and H9 dF at P6. (A) Metaphase spread and (B) karyogram of H9 dF 




4.2.7. Adherence of freeze-thawed H9-F for H9 hESCs culture 
 
The mitomycin C inactivated H9 ebF and H9 dF retained normal 
morphologies after thawing and could attach to the culture plate within 24 








Figure 12. Morphologies of inactivated H9 ebF and H9 dF after thawing. 
Freeze-thawed H9 ebF and H9 dF could attach to the gelatin-coated plate 
within 24 hours after seeding and retain normal morphologies. The scale 



















The H9 hESCs cultured on autologous feeders, MEF and MatrigelTM were 
split every 5-7 days, depending on the size of colonies and growing conditions. 
Approximate 65 passages of H9 hESCs had been cultured on H9 ebF and H9 
dF. And approximate 22 passages of H9 hESCs were propagated on 
MatrigelTM with the use of commercial medium mTeSRTM1. The hESCs on 
autologous feeders were propagated in compact morphology with distinct 
borders and high nucleus-to-cytoplasm ratios. The morphologies of these 
hESCs were similar to those cultured on MEF feeders (Figure 13-15). 
However, H9 hESCs cultured on feeder-free MatrigelTM formed monolayer 
colonies. These colonies were composed of homogenous cells and their 
morphologies were different from the cells cultured on feeder cells (Figure 16). 
These observations are consistent with the description of the medium 

















Figure 13. Morphologies of H9 hESCs on inactivated H9 ebF feeder. Cell 
colonies were compact with distinct borders and clear nuclei. The scale 
bars indicate 500μm. The asterisk indicates the passage number after 
cryopreservation. 
 










Figure 14. Morphologies of H9 hESCs on inactivated H9 dF feeder. Cell 
colonies were compact with distinct borders and clear nuclei. The scale 















Figure 15. Morphologies of H9 hESCs on inactivated MEF feeder. Cell 
colonies were compact with distinct borders and clear nuclei. The scale 













Figure 16. Morphologies of H9 hESCs on feeder-free MatrigelTM. H9 
hESCs cultured on MatrigelTM in mTeSRTM1 medium formed monolayer 
colonies whose morphologies were different from those on feeder cells. 
The scale bars indicate 500μm. The asterisk indicates the passage number 
after cryopreservation. 
Results 
4.3.2. Viability after cryopreservation 
 
Cryopreservation is a conventional technique for long-term storage of cells. 
The hESCs have been reported to be prone to cryopreservation-induced 
apoptosis (Fu et al., 2009; Heng et al., 2005; Heng et al., 2006; Heng et al., 
2009). Therefore, the impact of conventional cryopreservation procedure on 
H9 hESCs cultured on autologous feeders was studied. After cryopreservation, 
H9 hESCs could survive on both autologous feeder and feeder-free MatrigelTM 
efficiently and maintain normal phenotypes, suggesting the supportive abilities 
of in-house derived autologous H9-F for cryopreserved H9 hESCs. The 
morphologies of hESC colonies are shown in Figure 13-16 with asterisk 
marks.   
 
4.3.3. Expressions of undifferentiated markers 
 
After propagation for 22 passages, the undifferentiated status of H9 hESCs 
cultured on autologous feeders, MEF and feeder-free MatrigelTM were 
confirmed by positive immunofluorescence staining of hESC-specific markers, 
























MatrigelTM SSEA-3/4 MatrigelTM Tra-1-60 MatrigelTM Oct4 
Figure 17. Immunofluorescence staining of hESC undifferentiated markers. H9 
hESCs were propagated on autologous H9-F feeders, MEF feeder and 
feeder-free MatrigelTM for 22 passages before being subjected to 
immunofluorescence staining. Strong positive staining of hESC 
undifferentiated markers, Oct4, SSEA-3/4 and Tra-1-60, was observed in H9 
ebF-supported, H9 dF-supported, MatrigelTM-supported and MEF-supported 








4.3.4. ALP activities  
 
After 22 passages on autologous feeders and MatrigelTM, H9 hESCs 
retained high levels of membrane ALP activities and showed red dye 
deposition on the surface of the colonies (Figure 18). The stainings were 
similar to those of the H9 hESC colonies cultured on MEF feeder, suggesting 














H9 ebF H9 dF 
Figure 18. Positive ALP staining of H9 hESCs cultured in various culture 
systems. After 22 passages on autologous feeders and MatrigelTM, H9 hESCs 
retained high levels of membrane ALP activities and showed red dye deposition 




4.3.5. Comparisons of H9 hESCs on H9-F, MEF and feeder-free MatrigelTM 




The proliferation abilities of H9 hESCs in various culture systems were 
measured by both PI staining and CFDA-SE labeling after 44 passages and 50 
passages respectively in culture. PI staining measures the DNA contents of 
cells. Cells with DNA content within the range between diploid chromosome 
and double diploid chromosome are going through the DNA synthesis (S) 
phase and about to enter the second gap (G2) phase and the mitosis (M) phase. 
Therefore, to some extent, the percentages of cells in S phase and G2/M 
phases demonstrate the proliferation activity of cells. Figure 19 shows the 
histogram profiles of H9 hESCs after PI staining. In the H9 ebF-supporting 
system, 63.12±8.71% of H9 hESCs resided in the S and G2/M phases. In the 
H9 dF-supporting system, 64.66±3.41% of H9 hESCs were in the S and G2/M 
phases. In the MEF-supporting system, 62.51±6.54% of hESCs were in the S 
and G2/M phases. There was no statistical difference in the distributions of 
cell cycle phases of H9 hESCs among the H9 ebF system, the H9 dF system 
and the MEF system (p>0.05). However, in the feeder-free system, the 




which was significantly higher than those in feeder-dependent systems 
(p<0.01).  These results suggest that H9 hESCs proliferated faster in 
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Figure 19. Cell cycle analysis of H9 hESCs by PI staining. The cell 
contents of H9 hESCs were measured by PI staining followed by flow 
cytometric analysis. There was no statistical difference in the 
distributions of cell cycle phases of H9 hESCs among the H9 ebF 
system, the H9 dF system and the MEF system (p>0.05). However, H9 
hESCs proliferated significantly faster on MatrigelTM in feeder-free 
conditions (p<0.01). S indicates DNA synthesis phase. G2 indicates 





These findings were confirmed by tracking the division of H9 hESCs using 
CFDA-SE labeling. The fluorescence intensities of CFDA-SE labeled H9 
hESCs showed no significant difference among four culture systems on day 3 
(D3). However, on day 5 (D5), the fluorescence intensities of H9 hESCs 
grown in feeder-free system dropped down dramatically and was significantly 















































Figure 20. Cell division tracking of H9 hESCs by CFDA-SE labeling. On 
day 5 (D5), the fluorescence intensities of H9 hESCs grown in feeder-free 
system dropped down dramatically and was significantly lower than those 




4.3.5.2. Maintenance of undifferentiated states 
The abilities to maintain the undifferentiated states of hESCs by H9 ebF and 
H9 dF were compared. The expressions of undifferentiated markers (Oct4, 
Nanog and Sox2) and three germ layer markers (NeuroD1, Brachyury and 
AFP) by hESCs were analyzed by qualitative conventional RT-PCR. Results 
showed that H9 hESCs cultured on both H9 ebF and H9 dF expressed Oct4, 
Nanog and Sox2 from P1 to P20 (Figure 21).  A transient spike of NeuroD1 
expression could be observed in H9 hESCs from H9 dF and MEF culture 
systems. In addition, NeuroD1 was commonly present in H9 hESCs 
propagated on MatrigelTM, which has not been reported by the manufacturers. 
The endoderm marker AFP was occasionally expressed in 
MatrigelTM-supported H9 hESCs as well. No detectable expression of 















Figure 21. Comparison of gene expression profiles of H9 hESCs. H9 hESCs cultured in 
various systems for 20 passages were subjected to RT-PCR analysis. Undifferentiated 
hESC markers: Oct4, Nanog, Sox2. Ectoderm marker: NeuroD1. Mesodermal marker: 
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The expression of undifferentiated markers (Figure 22) and three germ layer 
markers (Figure 23) by H9 hESCs were further compared by real-time 
RT-PCR. After 20 passages, H9 hESCs grown on H9 dF feeders expressed 
significantly lower level of Sox2 than those on H9 ebF feeders (Figure 22C). 
Meanwhile, H9 hESCs cultured on H9 dF feeder showed higher extent of 
spontaneous differentiation by expressing significantly higher level of 
NeuroD1, Brachyury and AFP at P10, P5 and P20 respectively (Figure 23). 
We also observed persistent up-regulation of NeuroD1 in H9 hESCs cultured 
on MatrigelTM, which was consistent to the results obtained in conventional 

















Figure 22. Real-time RT-PCR analysis of undifferentiated markers in H9 
hESCs. Expression of Oct4, Nanog and Sox2 by H9 hESC were analyzed at 
passage 1(P1), passage 10 (P10) and passage 20 (P20). After 20 passages, 
H9 hESCs grown on H9 dF expressed significantly lower level of Sox2 
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Figure 23. Quantification of spontaneous differentiation of H9 hESCs by 
real-time RT-PCR. The expression of three germ layers markers were 
characterized at every 5 passages over a period of 20 passages. H9 hESCs 
cultured on H9 dF feeder showed higher extent of spontaneous differentiation by 
expressing significantly higher level of NeuroD1, Brachyury and AFP at P10, P5 
and P20 respectively (p<0.05). Feeder-free system showed persistent high 
expression of NeurD1 from P5 onwards except P10.  
Results 
4.3.5.3. Percentages of undifferentiated H9 hESCs 
 
At P40, the purity of undifferentiated H9 hESCs was analyzed by the 
evaluation of the Oct4 positive and SSEA-3/4 positive cells using flow 
cytometric analysis. The results are shown in Figure 24 and Figure 25. 
For both Oct4 staining and SSEA-3/4 staining, two populations of H9 
hESCs with different fluorescence intensities were present. For the cells gated 
in R1, there was no significant difference in the percentages of cells 
expressing Oct4 and SSEA-3/4 among four culture systems. However, for the 
cells gated in R2 which showed higher fluorescence intensity of Oct4 and 
SSEA-3/4, the percentage of H9 hESCs in the MEF system was significantly 
higher than those of the cells cultured in autologous culture systems. 
Furthermore, for SSEA-3/4 staining, the percentage of R2-gated H9 hESCs 
was significantly higher in the H9 ebF system than in the H9 dF system.  
In summary, quantitative data suggest a better maintenance of 
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Figure 24. Flow cytometric analysis of hESCs-specific marker Oct4. Two 
populations of H9 hESCs with different fluorescence intensities were 
present in four culture systems. There was no significant difference in the 
percentages of cells gated in R1. The percentages of R2-gated cells were 
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Figure 25. Flow cytometric analysis of hESCs surface marker SSEA-3/4. 
Two populations of H9 hESCs with different fluorescence intensities were 
present in four culture systems. There was no significant difference in the 
percentages of cells gated in R1. The percentages of R2-gated cells were 
significantly lower in autologous systems than in MEF systems (p<0.05). 
Furthermore, the percentage of R2-gated H9 hESCs was significantly 







4.3.5.4. Maintenance of pluripotency  
   
  The pluripotent differentiation capabilities of H9 hESCs propagated in 
various culture systems were compared by in vitro EB formation and in vivo 
teratoma formation. Figure 26A shows a teratoma formation in the left hind 
leg of a SCID mouse injected with H9 hESCs. Figure 26B demonstrates the 
control mouse without injection.  
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Figure 26. Teratoma formation in SCID mouse. (A). Teratoma clump 
formed in SCID mice after injection with H9 hESC. (B) Negative control. 
 
 
Teratoma clump was firstly observed in SCID mice 5 weeks after injection 
with H9 hESCs which had been cultured on H9 ebF feeders for 60 passages. 
The SCID mice injected with H9 dF-supporting H9 hESCs developed 
detectable teratoma from 7 weeks onwards.  Histological analysis was 
performed to examine the presence of tissues derived from three germ layers 






















Figure 27. H&E staining of teratoma sections. (A) Positive teratoma 
formation in SCID mice injected with H9 hESCs. (a)-(d): Teratoma 
sections derived from H9 hESCs cultured on MEF system. (a). Neural 
rosettes derived from ectoderm. (b). Cartilage derived from mesoderm. (c). 
Smooth muscle derived from mesoderm. (d). Glandular epithelium derived 
from endoderm. (e)-(h): Teratoma sections derived from H9 hESCs 
cultured on H9 ebF. (e). Neural rosettes derived from ectoderm. (f). 
Cartilage derived from mesoderm. (g). Smooth muscle derived from 
mesoderm. (h). Glandular epithelium derived from endoderm. (i)-(l): 
Teratoma sections derived from H9 hESCs cultured on H9 dF. (i). Neural 
rosettes derived from ectoderm. (j). Cartilage derived from mesoderm. (k). 
Smooth muscle derived from mesoderm. (l). Glandular epithelium derived 
from endoderm. Bars indicate 100μm. (B) Negative teratoma formation in 
SCID mice injected with H9-F. Photos showed the muscle tissue after H&E 




To exclude possible confounding effects of autologous feeder cells, the H9 
ebF and H9 dF cells at P6 without inactivation were injected into SCID mice. 
Neither of them developed teratoma even after 12 weeks post-injection, 
confirming the non-tumorigenicity properties of H9-F (Figure 27B).  
To further compare the pluri-differentiation potential, H9 hESCs propagated 
in various systems were subjected to in vitro EB formation (Figure 28A). EB 
specimens were collected at 4 designed time points (5 days, 7 days, 14 days 
and 21 days) for RT-PCR and real-time RT-PCR analysis. RT-PCR results 
demonstrated successive increase in the expression of three germ layer 
markers in EB samples from day 5 to day 21 (Figure 28B). Real-time RT-PCR 
data showed that the day 21 EB samples from H9 ebF culture system 
expressed a significantly higher level of ectoderm markers Pax and endoderm 
marker AFP than from H9 dF culture system (Figure 29). Additionally, 
accelerated expressions of NeuroD1 and Pax were observed in EB samples 
derived from the feeder-free system. This finding is consistent to the 
observation of the predominant expression of NeuroD1 in the feeder-free 
MatrigelTM-supported H9 hESCs as described in 4.3.5.2.  
In summary, the teratoma formation confirmed the pluripotency of H9 
hESCs cultured on autologous feeders. Furthermore, the real-time RT-PCR 
data decided that H9 ebF had a better effect on maintaining the pluripotency of 























































Figure 28. Characterization of the pluripotency of H9 hESCs by in vitro EB 
formation. (A) Morphologies of EB aggregate after 7 days in suspension. H9 
hESCs were differentiated and formed EB aggregates after cultivation in EB 
medium. FF stands for feeder-free. The scale bars indicate 100μm. (B) 
Digital photos of agarose gel electrophoresis after RT-PCR analysis on EB 
specimens. Numbers indicate the numbers of days for the EB formation. FF 





























































































Figure 29. Quantitative characterization of the pluripotency of H9 hESCs. 21 
days EB samples were subjected to real-time RT-PCR analysis for expression 
of three germ layers markers. EB specimens from H9 ebF culture system 
expressed a significantly higher level of ectoderm markers Pax and endoderm 
marker AFP than EB specimens from H9 dF culture system (p<0.05). 
Additionally, an accelerated expressions of NeuroD1 and Pax were observed in 





Results from 4.3.5.3 and 4.3.4.5 collectively suggested a better supportive 
ability of H9 ebF than H9 dF. Finally, to confirm the genomic integrity of H9 
ebF-supported H9 hESCs, the H9 hESCs that had been propagated on H9 ebF 
feeders for extended period (30 passages) were subjected to cytogenetic 
analysis using mFISH. H9 hESCs were able to retain normal 46,XX karyotype 











Figure 30. Cytogenetic analysis of H9 hESCs by mFISH. The normal diploid 
karyotype (44,XX) of H9 hESCs that had been propagated on H9 ebF cells 
for 30 passages were detected. (A) Metaphase spread of H9 hESCs. (B) 
Karyogram of H9 hESCs after mFISH probing. 
 
  In summary, H9 ebF cells played a better effect on maintaining the 
undifferentiated states and the pluripotency of H9 hESCs than H9 dF. 
Therefore, H9 ebF is the optimal autologous feeder to support undifferentiated 




4.4. Characterization of hESCs on H9 ebF-derived ECM in xeno-free, serum-free 
and feeder-free conditions 
   
4.4.1. Establishment of ECM stratum with H9 ebF 
 
The optimal autologous feeder cells, H9 ebF, were seeded on human collagen type 
IV-coated plates to construct xeno-free and feeder-free ECM stratum for hESCs 
culture. After freeze-thaw process, H9 ebF cells were completely removed, while their 







Figure 31. Deposition of ECM from H9 ebF. (A) H9 ebF cells before freeze-thaw 
process. The scale bar indicates 500m. (B). H9 ebF-derived ECM after extraction 







4.4.2. Characterization of H9 ebF-derived ECM 
 
To study the composition of autologous ECM, the H9 ebF were successfully 
attached on coverglass chamber without collagen IV coating. The 3-D structure of H9 
ebF-derived ECM was analyzed by confocal microscopy (Figure 32) The ECM 
substrate was previously reported to be the mixture of fibronectin, laminin and 
collagen type I, IV, VI fibrillar lattices. (Amenta et al., 1986; Beacham et al., 2007; 
Bruce Alberts, 2002; Saylam et al., 2002). Consistent to previous studies, our results 
showed positive staining of fibronectin, laminin and collagen type VI in H9 
ebF-derived ECM substrate. However, our result showed negative staining of collagen 

































Figure 32. Confocal images of the 3-D structure of fibroblast-derived ECM. (A) 
Immunofluorescence staining of ECM with anti-fibronectin antibody. (B) 3-D view 
of fibronectin fibrillar lattices shown in combination of phase contrast image and 
fluorescence image. (C) Immunofluorescence staining of ECM with anti-laminin 
antibody. (D) 3-D view of laminin fibrillar lattices shown in combination of phase 
contrast image and fluorescence image. (E) Immunofluorescence staining of ECM 
with anti-collagen VI antibody. (F) 3-D view of collagen VI fibrillar lattices shown 
in combination of phase contrast image and fluorescence image. The scale bars 
indicate 50m.   
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2 is an improved version of mTeSR
TM
1 medium by excluding non-human 
proteins. The combination of H9 ebF derived ECM and TeSR
TM
2 provides a xeno-free, 
serum-free and feeder-free environment for hESCs culture. In this study, H1 and H9 
hESCs had been propagated on MEF feeder for 50 and 56 passages respectively 
before transfer to ECM system. The hESCs cultured on ECM retained cell aggregate 
structure and formed colonies with distinct border as those on MEF feeder. In this 
ECM system, both H1 and H9 hESCs had been expanded for 20 passages. The 
















H1 on ECM H1 on Matrigel
TM
 H1 on MEF 
H9 on MEF H9 on Matrigel
TM 
H9 on ECM 
Figure 33. Morphologies of H1 and H9 hESCs cultured on H9 ebF-derived ECM, 
Matrigel
TM
 and MEF respectively. Both H1 and H9 hESCs were cultured on ECM 
and Matrigel for 20 passages in TeSR
TM
2 medium. H1 and H9 hESC retained the 
cell aggregate structure and formed colonies with distinct border as those on MEF 
feeder. The scale bars indicate 200m. 
Results 
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4.4.4. Maintenance of undifferentiated states of hESCs  
 
After propagation on ECM for 10 passages, the H1 and H9 hESCs were subjected 
to immunofluorescence staining for hESC-specific markers, including Oct4, 
SSEA-3/4 and Tra-1-60. Strong positive fluorescence signals of all three markers 
were detected on ECM-supported and Matrigel
TM
-supported H1 and H9 hESCs 























Figure 34. Immunofluorescence staining of hESCs for expression of 
hESC-specific markers. H1 and H9 hESCs were expanded on H9 ebF-derived 
ECM and Matrigel
TM
 for 10 passages before being subjected to 
immunofluorescence staining. Strong positive fluorescence signals of three 
hESC markers (Oct4, SSEA-4 and Tra-1-60) were detected on ECM-supported 
and Matrigel
TM
-supported H1 and H9 hESCs. The scale bars indicate 500m.  
H1 on ECM 
Phase contrast Oct4 SSEA-3/4 Tra-1-60 
H9 on ECM 
Oct4 Phase contrast SSEA-3/4 Tra-1-60 
H1 on Matrigel
TM 
Oct4 Tra-1-60 SSEA-3/4 Phase contrast 
H9 on Matrigel
TM 
Oct4 Tra-1-60 SSEA-3/4 Phase contrast 
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  The gene expressions of undifferentiated markers were consistently detectable in 
both H1 and H9 cells at both P10 and P20 after RT-PCR analysis (Figure 35). In 
addition, a low level of NeuroD1 and AFP were also present in hESC cultures, which 
was consistent with the observations in 4.3. For quantitative analysis, hESCs were 
subjected to real-time RT-PCR at P20. A significantly higher level of Nanog 
expression was observed in ECM-supported H9; and a significantly higher level of 
Sox2 expression was observed in Matrigel
TM
-supported H1 (Figure 36A). In addition, 
the AFP expression was significantly higher in Matrigel
TM
 system than that in ECM 














Figure 35. Gene expression patterns of hESCs by RT-PCR analysis. 
Undifferentiated markers Oct4, Nanog and Sox2 were expressed 
consistently at P10 and P20 in both ECM and Matrigel
TM
 systems. 
Housekeeping gene -actin served as internal control. A low level of 
NeuroD1 and AFP were also present in hESC cultures. 
Results 
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Figure 36. Quantitative analysis of gene expression patterns of hESCs by 
real-time RT-PCR. Expression of undifferentiated markers (Oct4, Nanog 
and Sox2) and three-germ layer markers (NeuroD1, Brachyury and AFP) 
were evaluated. At P20, a significantly higher level of Nanog expression 
was observed in ECM-supported H9; and a significantly higher level of 
Sox2 expression was observed in Matrigel
TM
-supported H1. In addition, the 
AFP expression was significantly higher in Matrigel
TM
 system than that in 




4.4.5. Percentage of undifferentiated hESCs 
   
The undifferentiated hESCs were evaluated by the positive expression of Oct4 and 
SSEA-3/4. The percentages of Oct4 positive and SSEA-3/4 positive cells in hESC 
culture were tested at P19 and P20 respectively. The results showed the similar 
percentages of Oct4 positive and SSEA-3/4 positive hESCs in both ECM-supporting 
and Matrigel
TM






























































Figure 37. Analysis of percentages of undifferentiated hESCs by flow cytometry. 
Percentages of Oct4 positive and SSEA-3/4 positive hESCs (H1 and H9) on ECM 
and Matrigel
TM
 were quantified by flow cytometry. Flow cytometry histograms 
were demonstrated in (A) for Oct4 staining and in (B) for SSEA-3/4 staining. No 
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4.4.6. Proliferation of hESCs 
 
  The cell cycles of hESCs were analyzed on day 3 after plating. Both H1 and H9 
cultured on ECM showed the similar distribution in all cell cycle phases as those on 
Matrigel
TM


















Figure 38. Cell cycle analysis of hESCs (H1 and H9) on ECM and on 
Matrigel
TM
. The DNA contents of hESCs were stained by PI and 
analyzed by flow cytometry. The results suggested that hESCs on ECM 
and Matrigel
TM
 shared similar proliferation activities by showing similar 
distribution of cell cycle phases.    
Results 
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4.4.7. Pluripotency of hESCs 
   
To examine the pluri-differentiation potential of hESCs after long-term propagation 
on ECM, both H1 and H9 hESCs in ECM system were harvested after 10 passages to 
form EB in vitro. Then the gene expressions of three germ layer markers were 
evaluated in these EB. Results showed a steady increase of the expression of these 
















Figure 39. Expression of three germ layer markers in EB specimens. EB 
aggregates were derived from ECM-supported H1 hESCs and H9 hESCs. The 5D 
(day 5), 14D (day 14) and 21D (day 21) indicated the designed time points for EB 
collection. The EB samples demonstrated a steady increase in the expression of 
three germ layer markers along with the time in culture. Ectoderm markers: 
NeuroD1 and NF-68. Mesoderm markers: Brachyury and PPAR-. Endoderm 
markers: 1-AT and AFP. Housekeeping gene -actin served as internal control.   
Results 
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After 10 passages in ECM system, both H1 and H9 were injected into 5-week 
SCID mice to form teratomas in vivo. The teratoma clumps with detectable size were 
found at 6 weeks post-injection. The teratoma constituted a variety of tissue types 
originated from 3 germ layers, such as neural rosettes from ectoderm; cartilage, 
adipocytes and smooth muscle from mesoderm; and various types of endothelium 
















   
Figure 40. Teratoma formations by ECM-supported H1 hESCs. After 10 
passages in ECM system, H1 hESCs were injected into 5-week SCID mice to 
form teratomas in vivo. Teratomas were harvested at 9 weeks post-injection 
and characterized by H&E staining. H1 hESCs formed teratomas composed 
of various types of tissue types. Ad: adipocyte (mesoderm); Ca: Cartilage 
(mesoderm); CGE: colonic gut epithelium (endoderm); Ep: Respiratory, 
brush-border, epithelium (endoderm); GE: Grandular epithelium (endoderm); 
NR: neural rosettes (ectoderm); SM: smooth muscle (mesoderm). The scale 






































Figure 41. Teratoma formations by ECM-supported H9 hESCs. After 10 
passages in ECM system, H9 hESCs were injected into 5-week SCID mice to 
form teratomas in vivo. Teratomas were harvested at 9 weeks post-injection 
and characterized by H&E staining. H9 hESCs formed teratomas composed 
of various types of tissue types. Ad: adipocyte (mesoderm); Ca: Cartilage 
(mesoderm); CGE: colonic gut epithelium (endoderm); Ep: Respiratory, 
brush-border, epithelium (endoderm); GE: Grandular epithelium (endoderm); 
NR: neural rosettes (ectoderm); SM: smooth muscle (mesoderm). The scale 
bars indicated 500m.  
Results 
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4.5. Applications of ECM-supported hESCs  
   
  To test the flexibilities of ECM-supported hESCs in future clinical and 
experimental applications, we subject the ECM-supported hESCs to in vitro 
differentiation and to cytotoxicity testing.  
  
4.5.1. In vitro differentiation to osteogenic progenitors  
   
The ECM-supported hESCs can be induced to differentiate into osteogenic lineage. 
The H1 and H9 colonies detached from ECM were successfully attached to the 
gelatin-coated plate within 24 hours. The cells proliferated in osteogenic 
differentiation media and formed multilayer within 10 days. Detectable nodules 
appeared after 10 days. The mineralization was detected by positive Alizarin staining 




























4.5.2. Cytotoxicity testing of NaF on ECM-supported H9 hESCs by MTS assay  
  
  To study the application of ECM-supported H9 hESCs in cytotoxicity testing, we 
exposed ECM-supported H9 hESCs and H9 ebF to various concentrations of NaF. 
Matrigel
TM
-supported hESCs and immortalized human cell line CRL1486 served as 
controls. The mitochondrial activities were evaluated by MTS assay at both 2 hours 
and 24 hours post treatment. The lethal doses, 50% (LD50) were calculated 
accordingly and the results were summarized in Figure 43. For the short term 
treatment (2 hours), the LD50 of ECM-supported and Matrigel-supported H9 cells 
A B 
C D 
Figure 42. Alizarin Red staining of mineralized nodules differentiated from 
ECM-supported H1 and H9 hESCs. (A) Nodules differentiated from H1 hESCs. 
(B) Differentiated cells from H1 hESCs in control medium (DMEM with 10% 
FBS). (C) Nodules differentiated from H9 hESCs. (D) Differentiated cells from H9 




were significantly higher than H9 ebF and CRL1486 (p<0.05). However, for the 
long-term exposure (24 hours), H9 hESCs, H9 ebF and CRL1486 bore similar LD50. 
The results suggested that hESCs had higher tolerance to the NaF-induced short-term 
cytotoxic effects than their differentiated progenitor cell (H9 ebF) and immortalized 
somatic human cell line CRL1486. We also observed that hESCs cultured on ECM 
and on Matrigel
TM
 shared similar results, suggesting the flexibility of using 
ECM-supported hESCs to replace Matrigel
TM
-supported hESCs for future toxicity 



















Figure 43. Cytotoxic effect of NaF on H9 hESCs, H9 ebF and CRLl486. 
After short term (2 hours) treatment, H9 hESCs on both ECM and 
Matrigel
TM
 exhibited higher resistance to NaF-induced cytotoxicity than 
H9 ebF and CRL1486 (p<0.05). However, after 24 hours of exposure, 
both H9 hESCs, H9 ebF and CRL1486 shared similar tolerance to 
NaF-induced toxicity by displaying similar LD50.   






















































5.1 Feasibility of H9-F derivation 
 
In the present study and previous investigations, to eliminate xenogenic 
components and infectious pathogens from hESCs culture, autologous feeders 
were derived from hESCs through different methods to support hESC culture. 
Comparing autologous feeders derived from different methods and identifying 
an optimal way to develop an autologous feeder system would be of utmost 
importance for future establishment of clinical-grade hESCs.  
In this study, we successfully derived the autologous fibroblast H9-F from 
H9 hESCs with and without EB formation prior to induce differentiation and 
expansion. The ease of derivation with the autologous cell source, the human 
origin and the up-scalability of the cell source required for deriving H9-F make 
them ideal candidates for comparison, optimization and standardization of 
autologous feeder systems for hESC culture. In the stage 2 of this study, the 
phenotypes and genotypes of autologous fibroblast cells were characterized and 







5.2. Similarities and differences in the properties of H9 ebF and H9 dF 
 
 In this study, it was observed that both H9 ebF and H9 dF were highly 
proliferative at high doubling speed up to 20 passages. The high proliferation 
capability facilitates the large scale preparation of feeder cells with the same 
quality in a cost-effective and efficient way. The identities and purities of 
autologously-derived fibroblasts were monitored by flow cytometry for 
expression of various markers, including mouse MHC Id, human CD44 and 
human P4β.  
Mouse MHC Id describes the H2 hyplotype of MEF derived from CF-1 mice. 
Because both H9 ebF and H9 dF were derived from hESCs that had been 
supported by MEF. FACS analysis of Mouse MHC Id further verified that 
hESC-derived fibroblasts (H9 ebF and H9 dF) are depleted of contaminant 
MEF after continuous passaging. CD44 is a cell surface glycoprotein which is 
involved in cell adhesion and migration, wound healing, lymphocyte 
recirculation and metastasis (Haynes et al., 1989; Haynes et al., 1991; Rajarajan 
et al., 2008). CD44 has been reported to be present in many types of 
lineage-committed cells, including keratinocytes, endothelial cells, 
hematopoietic progenitor cells, myelomonocytic cells, lymphocytes, tumor cells 
and fibroblasts (Fichter et al., 1997; Hamada et al., 1998; Hiscox and Jiang, 
1997; Legras et al., 1997; Mackay et al., 1994; Romaris et al., 1995; Tuhkanen 
et al., 1999). However, the previous study demonstrated the lack of CD44 in 
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undifferentiated hESCs (Haegel et al., 1994). Therefore, the differentiation 
procedure of H9-F can be quantified by tracing the acquirement of CD44 
production. In this study, after splitting for 6 passages, H9 hESCs differentiated 
and gained CD44 production at protein level, suggesting the successful 
conversion from hESCs to differentiated cells. 
In addition, the fibroblast marker P4β was employed to further specify the 
cell type of H9-F. Gain of expression of P4β in both H9 ebF and H9 dF 
confirmed their fibroblastic identities. Flow cytometry analysis of P4β further 
characterized that the purities of fibroblast cells in two differentiated 
populations were above 99% after continuous two passages.   
  H9 ebF and H9 dF shared similar patterns of gene expression of cell type 
specific markers. Specifically, undifferentiated markers in H9 ebF and H9 dF 
diminished in a time-dependent manner and completely depleted after the 
fourth passage of expansion. Our finding contradicts to the published findings 
by Saxena et al (Saxena et al., 2008) that in their report, the Oct4 expression in 
autologous fibroblasts persisted for up to 25 passages. This difference might be 
due to the intensive differentiation of H9-F at the first passage by prolonged 
time in culture. Moreover, three germ layer markers were either absent or 
expressed at low levels in H9-F with the exception of PPAR-γ. In our study, a 
constitutive expression of PPAR-γ was present in H9-F at mRNA level. PPAR-γ 
(Peroxisome Proliferator-activated Receptor gamma) is a nuclear hormone 
receptor involved in cell activation, differentiation, proliferation and/or 
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apoptosis (Benayoun et al., 2001). PPAR-γ was originally characterized as a 
regulator in adipogenic differentiation and lipid metabolism (Tontonoz et al., 
1994). However, the expression of PPAR-γ has also been reported in human 
synovial fibroblast and lung myofibroblast (Kawahito et al., 2000; Marra et al., 
2000). Therefore, the expression of PPAR-γ in H9-F is not unexpected. In 
addition, the expression of epithelium marker cytokeratin 4 was absent at 
mRNA level in H9-F. Gene expression data further suggested the lineage 
restriction of H9-F to fibroblastic lineage and not to other lineages. Cytogenetic 
analysis identified the genomic integrity of H9-F. More importantly, the FGF-2 
expression was confirmed to be present at both mRNA level and protein level in 
H9-F. Human FGF-2 has been reported to play a key role for the retention of 
undifferentiated state and pluripotency of hESCs. The production of FGF-2 by 
H9-F suggested the feasibility of the development of autologous feeder systems 
from hESCs.  
Although H9 ebF and H9 dF share similarities in their identities and origins, 
they bear differences in various properties. Firstly, undifferentiated markers 
depleted faster in H9 ebF than in H9 dF. This difference could be explained by 
the pre-differentiation of EB formation prior to H9 ebF derivation. Secondly, 
the secretion of FGF-2 is significantly higher in H9 ebF than in H9 dF. The 
molecular mechanism underlying this finding is still unclear and requires future 
investigations.  
In summary, we showed the validities of two differentiation protocols for 
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derivation of autologous fibroblast cells from H9 hESCs. Therefore, both H9 
ebF and H9 dF were two autologous candidates to support growth of H9 hESCs. 
To verify their supportive potential, H9 ebF and H9 dF should be tested as 
feeder cells to support H9 hESCs for growth and maintenance of pluripotency. 
Moreover, in order to devise a stable and efficient culture system for expanding 
clinical-grade hESCs in future, the difference in the growth conditions of H9 
hESCs in the autologous feeder systems, the MEF system and the feeder-free 
system requires a systematic investigation.  
   
5.3. Comparison of supportive effect on the growth of H9 hESCs by H9 
ebF, H9 dF, MEF and feeder-free MatrigelTM 
 
5.3.1. The characteristics of H9 hESCs on H9-F 
 
Comparable to the supportive ability of MEF feeder, autologous feeders 
could maintain normal phenotypes and characteristics of H9 hESCs for 
prolonged culture up to 20 passages. Human ESCs were able to recover from 
cryopreservation, upon plating on both H9 ebF and H9 dF and retained normal 
morphology. Cytogenetically, H9 hESCs cultured on autologous feeders 
retained normal karyotypes without any chromosomal aberration. Additionally, 
we also demonstrated that neither H9 ebF nor H9 dF were tumorigenic after 
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intra-muscular injection into SCID mice, which further support the use of 
autologous feeder supported hESCs for the future possible clinical applications.  
 
5.3.2. Better effect on the maintenance of undifferentiated states of hESCs by 
H9 ebF in comparison with H9 dF 
 
We investigated the undifferentiated states of hESCs by analyzing their 
expression of hESCs-specific markers using real-time RT-PCR and flow 
cytometry. Quantitative data suggested differential supportive abilities of H9-F 
in hESC culture, at least in two aspects. Firstly, the hESCs propagated on H9 
ebF sustained significantly higher level of Sox2 expression than on H9 dF. 
Secondly, the degree of spontaneous differentiation in routine hESC culture was 
significantly lower in the H9 ebF system than in the H9 dF system. This finding 
was illustrated by lower expressions of three germ lineage markers NeuroD1, 
Brachyury and AFP in H9 ebF-supported hESCs than in H9 dF-supported 
hESCs. Thus, H9 ebF provides a relatively more stable support to maintain 
undifferentiated states of hESCs, when compared to H9 dF. 
Immunofluorescence staining followed by quantitative flow cytometric 
analysis of Oct4 and SSEA3/4 markers demonstrated two sub-populations of 
hESCs in each culture system. One sub-population (R2-gated) possessed strong 
Oct4 and SSEA-3/4 expression while the other sub-population (gated in R1 but 
not in R2) displayed weak Oct4 and SSEA-3/4 fluorescent intensities. Ideally, 
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hESCs should be maintained in culture without any trace of spontaneous 
differentiation. However, in routine hESC culture, a low level of spontaneous 
differentiation is inevitable, due to technical deviations in cell handling at every 
passage as well as the suboptimal culture conditions for growth of 
undifferentiated hESCs (Brimble et al., 2007; Hoffman and Carpenter, 2005). 
Reports from researchers demonstrated that several hESC markers, including 
Oct4, Nanog and SSEA-3/4, are useful markers to define the state of hESC, as 
their levels of expression are down-regulated upon hESCs differentiation (Cai 
et al., 2006). Hence, identification of the percentage of cells with different 
fluorescence intensities provides deeper insight to the culture condition of 
hESCs grown in different systems. Therefore, it is reasonable that after 
long-term culture, the hESCs expressing low Oct4 and SSEA-3/4 were 
growing in sub-optimal conditions and either differentiated or possessed a 
propensity to differentiate. In this study, the percentage of cells with strong 
SSEA-3/4 expression was significantly higher in the H9 ebF culture system 
than in the H9 dF culture system, suggesting a better supportive abilities of H9 
ebF than H9 dF. However, for both Oct4 and SSEA-3/4 markers, hESCs 
cultured on two autologous feeders showed lower percentages of strong positive 
cells than on MEF feeder and feeder-free MatrigelTM. These results indicate that 
to a certain extent, the supportive abilities of the autologous feeders were lower 




5.3.3. Better effect on the maintenance of pluripotency of hESCs by H9 ebF in 
comparison with H9 dF 
 
In our study, we have demonstrated the pluripotency of hESCs cultured in 
autologous feeder system by both EB formation and teratoma formation. It has 
been reported that the EB formation recapitulates the early embryonic 
development (Boyd et al., 2007; Feraud et al., 2001; Itskovitz-Eldor et al., 2000; 
Risau et al., 1988), in which cell-cell contact exists and gap junctions may be 
established (Kurosawa, 2007). Therefore, the differentiation capacities of 
hESCs can be reflected by the abilities of acquiring three germ layer markers of 
EB (Adewumi et al., 2007; Kim et al., 2007; Skottman et al., 2005; Tavakoli et 
al., 2009; Ware et al., 2006). Quantitative data demonstrated that EBs 
differentiated from H9 ebF-supported hESCs acquired significantly higher 
levels of Pax and AFP expression than the EBs from H9 dF-supported hESCs. 
As the degree of spontaneous differentiation of hESCs in the H9 ebF culture 
system was lower than that in the H9 dF culture system, it is speculated that H9 
ebF have a better effect on retaining the differentiation abilities of hESCs to 
ectodermal and endodermal lineages than H9 dF.  
 
In summary, the H9 ebF worked as a better autologous feeder for long-term 
culture of hESCs by providing a more stable support for the maintenance of 
both the undifferentiated states and pluripotency of hESCs. Moreover, the 
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secreted FGF-2 concentration was significantly higher in H9 ebF conditioned 
medium than in H9 dF conditioned medium. It has been well-known that FGF-2 
plays a crucial role in maintaining the characteristics of hESCs by cross-talking 
with BMP and TGF-β mediated signaling pathways (Dvorak et al., 2006; Wang 
et al., 2005; Xu et al., 2005). Therefore, it is speculated that the higher secretion 
amount of FGF-2 represents a better supportive ability of H9 ebF.  
In addition, H9 ebF were differentiated from the outgrowth of EBs. In human, 
at approximate 5-7 days of gestation, the embryo develops into a blastocyst in 
which the inner cell mass (ICM) is formed and is surrounded by 
trophoectoderm. Therefore, to maintain the undifferentiated growth of 
ICM-derived hESC in vitro, feeder cells resemble the native trophoectoderm to 
support prolonged growth of hESCs in culture. The development of EB prior to 
H9 ebF derivation might provide an embryo-like niche so as to support the 









5.3.4. Higher proliferation activities and ectoderm differentiation potentials of 
H9 hESCs in feeder-free MatrigelTM-mTeSRTM1 system 
 
In this study, we also compared the phenotypes of hESCs between 
feeder-dependent systems (MEF and H9-F systems) and the feeder-free 
MatrigelTM-mTeSRTM1 system. Two independent cell proliferation assays 
demonstrated the significant increase (p<0.05) in the proliferation rate of H9 
hESCs after transfer to the feeder-free system. Generally, hESC has a relatively 
large S phase with extremely rapid transit through the G0/G1 phase and 
detectable G2 bumps (Becker et al., 2006; Fu et al., 2009; Neganova et al., 
2009). In our study, we observed a significantly larger fraction of hESC 
population in S phase when they were maintained in the feeder-free culture 
condition. It was reported that mTeSRTM1 media stimulated FGF and TGF-beta 
pathways via FGF-2 and TGF-β, and regulated Wnt signaling pathway by 
GABA agonist and the non-specific WNT antagonist lithium chloride (Akopian 
et al., 2010; Klein and Melton, 1996). The high levels of these growth factors in 
the media might contribute to the increased cell division rate (Silva et al., 2010; 
Wang et al., 2008).  
In addition, in both hESC and EBs, significantly higher mRNA expressions 
of the ectoderm markers (NeuroD1 and Pax) were detected in the feeder-free 
system. The expression of NeuroD1 could be attributed to a high-level 
spontaneous differentiation of H9 hESCs after prolonged culture in the 
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feeder-free system with a propensity to differentiate into ectoderm lineages (Fu 
et al., 2009).  
Under our assay conditions, we demonstrated that H9 ebF was the optimal 
autologous feeder to maintain the growth of H9 hESCs. To our knowledge, we 
are the first to systemically compare two autologous feeders which are derived 
from H9 hESCs with or without EB formation prior to differentiation (Fu et al., 
2009). We are also the first to compare the feeder-free H9 hESC culture system 
with the feeder-dependent systems. This comparative study advances the 
establishment and standardization of autologous feeder systems for hESC 
culture. However, it is still noteworthy that the autologous feeder system still 
possesses some drawbacks. Firstly, culture media used in the autologous feeder 
system contain xenogenic components, which hinder the use of hESCs in future 
clinical applications. Secondly, the present autologous feeder might 
compromise the applications of hESCs in both experimental and clinical 
manipulations as discussed in 1.4. Therefore, we hold a great interest to 
develop a system with aid of an animal-component free medium together with 






5.4. Supportive effect of the xeno-free, feeder-free and serum-free system 
for the growth of hESCs  
 
5.4.1. Establishment of autologous feeder-derived ECM 
 
  In this study, the deposition of ECM by fibroblasts was induced by addition of 
ascorbic acid and dextran sulfate in culture medium. Previous studies 
demonstrate that the human fibroblasts cultured in ascorbic acid-containing 
medium are capable of increasing the deposition of ECM via inducing ECM 
assembly (Beacham et al., 2007; Guo et al., 2007; Sommer et al., 2007). It is 
also reported that dextran sulfate can accelerate the conversion of procollagen 
and the deposition of collagen by human fibroblasts (Bateman et al., 1986; 
Beacham et al., 2007; Lareu et al., 2007). In addition, previous studies reported 
that the prepared ECM substrates derived through this method closely resemble 
in vivo mesenchymal matrices and are composed mainly of fibronectin fibrillar 
lattices (Beacham et al., 2007). Therefore, in our study, we used both ascorbic 
acid and dextran sulfate to induce the ECM production by H9 ebF.  
Instead of a detergent lysis method (Beacham et al., 2007; Hedman et al., 
1979; Klimanskaya et al., 2005), we adopted a freeze-thaw process to extract 
ECM (Meng et al., 2010). Conventionally, the ECM was isolated by sequential 
treatment with detergent-containing buffer (such as Triton-X 100 and sodium 
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deoxycholate) and hypotonic buffer in the presence of protease inhibitor 
(Hedman et al., 1979; Lareu et al., 2007). This chemical lysis strategy requires 
additional washing steps to completely remove cell debris and detergent 
remnants. In contrast, our freeze-thaw method only requires a one-step freezing, 
followed by 3 times rinsing with PBS. The exclusion of detergent in the 
freeze-thaw method eliminates the possible detrimental effects caused by 
remnant detergent, such as loss of viability, nonspecific lysis of cell membrane 
and inhibition of cell proliferation (Picache et al., 2004; Rotunda et al., 2004).  
 
5.4.2. Characterization of H9 ebF-derived ECM   
 
  The composition and structure of ECM were characterized by fluorescent 
confocal microscopy. Consistent to previous reports (Beacham et al., 2007), the 
H9 ebF-derived ECM composed of fibronectin fibrillar lattices. In addition, two 
fibrous ECM proteins, laminin and collagen type VI, interconnected closely 
with fibronectin to construct a 3-D structure of ECM. However, collagen type I 
and collagen type IV were not present in this autologous feeder-derived ECM. 
This observation was consistent to the report of Rancourt et al (Meng et al., 
2010), but was contradictory to the report of Raghunath et al (Lareu et al., 2007). 
In Raghunath’s report, the cell lines used were embryonic lung fibroblast and 
adult hypertrophic scar fibroblast. It is well-known that collagen type I is the 
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most abundant collagen protein in human body (Di Lullo et al., 2002; Stein et al., 
2009), and can be found in many tissues, such as scar, tendon, skin, artery walls, 
endomysium of myofibrils, fibrocartilage and organic part of bones and teeth 
(Rehn, 2008). Different from collagen type I, collagen type IV is present only in 
basement membranes and is produced by limited cell types, such as epithelial 
cells, endothelial cells, muscle, nerve cells and basal cells of epithelium 
(Cormack, 2001; Garant, 2003). The absence of collagen type I and type IV in 
H9 ebF-derived ECM suggest the unique properties of hESC-derived 
fibroblasts rather than the collagen type I and type IV-producing fibroblasts 
derived from the tissues mentioned above.    
Among the composition of H9 ebF-derived ECM, fibronectin is one of the 
non-collagen matrix macromolecules that contribute to both the matrix 
organization and cell attachment (Bruce Alberts, 2002). It exists as a fiber 
component in ECM and in soluble form in body fluids (Chen and Mosher, 1996). 
Numerous studies documented the supportive abilities of fibronectin alone or 
together with other ECM components to support the undifferentiated growth of 
hESCs in media composed of various growth factors (Amit et al., 2004; Amit 
and Itskovitz-Eldor, 2006; Ludwig et al., 2006). Another component of H9 
ebF-produced ECM, collagen type VI, is a beaded microfilament (Bruns, 1984) 
that is present in most tissues, including cornea fibroblast (Guo et al., 2007; 
Zimmermann et al., 1986), cartilage (Ayad et al., 1984), skin (Keene et al., 1988) 
and muscle (Hessle and Engvall, 1984). It is also found concentrated near 
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basement membranes of nerves, blood vessels, and fat cells although in a less 
organized state (Keene et al., 1988). The filamentous network formed by 
collagen type VI plays an anchoring function (Keene et al., 1988). However, the 
knowledge of the role of collagen type VI plays in hESC growth is limited. 
According to our data, it might be worth speculating that collagen type VI 
occur in conjunction with fibronectin to form a matrix network, necessary for 
support of hESC culture.  
One more component of H9 ebF produced ECM, laminin, is the main 
component of basement membranes in human tissues (Aumailley et al., 2005) 
and is reported to support the growth of hESCs (Beattie et al., 2005; Li et al., 
2005; Rosler et al., 2004). The hESCs anchor with laminin by the 
laminin-specific receptor formed by integrin α6 and β1 (Xu et al., 2001).   
   
5.4.3. Cultivation of H9 and H1 hESCs on ECM 
 
  Unlike the hESCs on MatrigelTM, the hESCs on H9 ebF-derived ECM kept 
the similar morphology as those on MEF. The cells were densely compacted 
and aggregated to form colonies with 3-D structure. The reason of this 
difference could be the utilization of 3-D matrix substrate in ECM system. It has 
been reported that the fibroblast-derived ECM closely resemble in vivo 
mesenchymal matrices (Beacham et al., 2007). Therefore, the cultivation of 
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hESCs on H9 ebF-derived ECM may resemble the MEF culture system by 
acquiring information physiologically relevant to cell structures and functions 
through ECM-hESC interactions (Cukierman et al., 2001).  
  In our study, we applied a newly developed animal-component free medium 
TeSRTM2 to support the culture of hESCs in feeder-free and xeno-free 
conditions. Unlike previous studies (Meng et al., 2010; Pakzad et al., 2010), 
ROCK inhibitor Y-27632 was not supplemented into the feeder-free TeSRTM2 
media. Instead, in order to increase the number of attached colonies after 
passage, we reduced the splitting ratio from 1:6 to 1:3. The elimination of 
ROCK inhibitor in our culture assay may prevent the possible detrimental 
effects of Y-27632 on the expansion and survival of hESCs (Bueno et al., 
2010).  
 
5.4.4. Characterization of ECM-supported hESCs. 
 
  In this study, the maintenance of hESCs undifferentiated state by autologous 
feeder-derived ECM was confirmed by the positive staining of hESC-specific 
markers (Oct4, SSEA-4, Tra-1-60) and the gene expression of undifferentiation 
markers (Oct4, Nanog and Sox2). The retaining of hESCs pluripotency by 
autologous feeder-derived ECM was also verified by the EB and teratoma 
formation. Moreover, the proliferation rate of hESCs cultured on autologous 
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feeder-derived ECM was comparable to that on commercial MatrigelTM, which 
was certified by the cell cycle analysis. These results validate the application of 
autologous feeder-derived ECM for hESC culture. However, after 20 passages 
in the feeder-free culture systems, the expressions of undifferentiated markers 
Nanog and Sox2 significantly increased in the ECM-supported H9 and the 
MatrigelTM-supported H1 respectively. This subtle and inconsistent difference 
could be due to the inevitable fluctuations in the qualities of hESCs during 
routine culture as reported previously (Rosler et al., 2004). In addition, the 
degree of spontaneous differentiation of hESCs was lower in the ECM system 
than in the MatrigelTM system as less AFP gene expression was detected. It 
suggests a more stable supportive ability of ECM than MatrigelTM. 
  
5.5. ECM-supported hESCs are applicable for regenerative medicine and 
cytotoxicity testing  
 
  In this study, we also discussed the possible pre-clinical and experimental 
applications of ECM-supported hESCs. It is well known that hESCs hold 
differentiation potentials to develop into all derivatives of three germ layers. 
Therefore, hESCs can serve as a universal bank of cells from which specific 
cells may be isolated for cell replacement therapy. For example, the derivation 
of osteogenic cells form hESCs could be an alternative strategy for regeneration. 
The differentiation progress of hESCs to osteogenic lineage can also help 
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researcher to investigate the bone formation at early embryo stages. In this study, 
we confirmed the osteogenic differentiation potential of ECM-supported hESCs 
by detecting the nodule formation using Alizarin red staining. However, before 
going to bedside application, the hESC-differentiated osteogenic cells need to 
be purified and screened for tumorigenicity to prevent unwanted tumor 
formation after transplantation.  
  As discussed previously, pluripotent hESCs can recapitulate cellular 
developmental processes and gene expression patterns of early embryogenesis 
during in vitro differentiation (Rohwedel et al., 2001). Therefore, hESCs and 
their derivatives are also better suited to analyze embryotoxic effect of chemical 
compounds and substances as in vitro models (Krtolica et al., 2009; Mehta et al., 
2008). Sodium fluoride (NaF) is a commonly-used chemical compound that 
present in various dental materials, especially in toothpaste. NaF has been 
classified as toxic by both inhalation and ingestion 
(http://www.jtbaker.com/msds/englishhtml/S3722.htm). However, the toxic 
effect of NaF in the human embryogenesis has not been well documented. 
Therefore, the unique features and properties of hESCs suggest the utilization 
of hESCs in the embryotoxicity testing of NaF. In this study, H9 hESCs in 
feeder-free conditions were exposed to various concentrations of NaF for both 
short-term (2 hours) and long-term (24 hours) treatments. The H9 
hESC-derived H9 ebF and ATCC immortalized cell lines CRL1486 were also 
included for comparison. The objective is to investigate the differential 
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tolerance abilities of human cells with different cellular properties. The testing 
results suggested that for short term treatment, the H9 hESCs cultured on both 
MatrigelTM and autologous feeder-derived ECM held significantly higher 
tolerance to NaF-induced cytotoxic effects than differentiated progenitors and 
immortalized cell lines after short-term exposure. This result is consistent to the 
studies reported previous. Researchers detected that hESCs display a higher 
resistance to both genetic stress and oxidative stress than primary explanted 
somatic cells and differentiated progenitor cells respectively (George et al., 
2009; Vinoth et al., 2008). The possible reasons underlying this difference could 
be that the differentiated and immortalized cell lines possess higher mitotic 
activity and metabolism, therefore, more sensitive than the undifferentiated 
hESCs to the cytotoxic effect caused by NaF (Oh and Choo, 2006). Another 
possible reason is that during long-term expansion with high proliferation rate, 
the differentiated and immortalized cells accumulate higher level of genomic 
aberrations than hESCs, therefore is more vulnerable to chemical induced 
cytotoxicity. Alternatively, a possible conjecture is that organisms would invest 
more heavily in stress response and corrective mechanisms at earlier 
developmental stages compared to later developmental stages, simply because 
manifestation of abnormalities at early developmental stages has far more 
serious consequences than manifestation of similar abnormalities at later stages 
(George et al., 2009). However, for long-term treatment, undifferentiated 
hESCs, H9 ebF and CRL1486 shared similar tolerance to NaF-induced toxic 
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effect by displaying similar level of LD50. This phenomenon suggested that for 
long-term treatment, the NaF caused detrimental effects overwhelm the cellular 
reparatory mechanisms present in hESCs. Therefore, this observation suggested 
necessaries of further investigations on the mechanisms of cytotoxic effects 
induced by NaF. It also provided useful information to dentists on how to 
minimize the unwanted side effects caused by NaF components present in 
dental materials.  
 
5.6. Animal Model 
   
It is encouraged that hESCs hold great potentials for both clinical and 
experimental manipulations. Pluripotency is one of the important criteria 
required to check before subjecting hESCs to various applications. Currently, 
the most promising test of pluripotency is the teratoma formation which is 
comprised of derivatives of all three germ layers in animals in which ES cells 
are injected. Therefore, the animal models must be immunodeficient and 
tolerant for the development of teratoma from xenogenic sources. Other 
selecting factors include the size of the animals, the cost of feeding and the 
facility for histological analysis. Two mouse models are available nowadays 
with deficiency in their immune systems, including nude mouse and SCID 




leading to the absence of thymus. Previous studies demonstrated the residual 
immunoreactivity in nude mice against xenografts. The other model, SCID 
mouse, has disruptions in both B-and T-cell lymphoid development, resulting 
in low serum immunoglobulin levels and the lack of functional T cells (Bosma 
et al., 1983; Hendrickson, 1993). Therefore, the SCID mouse is expected to be 
a better host in which to perform preclinical studies on human diseases and 
xenografts (Sausville and Burger, 2006). SCID mouse has also been proved to 
be a superior host for human transfer experiments (Hendrickson, 1993). 
Therefore, in this study, we chose SCID mice as the animal model to study the 
pluripotency of hESCs by monitoring the development of teratoma after 














































Conclusions and recommendation for future study 
  In summary, the stage 1 results have demonstrated the successful derivation 
of H9 ebF and H9 dF from H9 hESCs. The stage 2 results have illustrated the 
identities, the fibroblastic properties, the purity and the chromosome 
integrities of both H9 ebF and H9 dF. In this stage, it is also shown that the H9 
ebF could secrete a higher level of FGF-2 than the H9 dF. The stage 3 results 
have defined the H9 ebF as the optimal autologous feeder because they 
provided stronger supportive effects for the long-term growth of H9 hESCs. In 
stage 4, a feeder-free, serum-free and xeno-free culture condition was 
constructed with H9 ebF-derived ECM and mTeSRTM1. The supportive 
abilities of H9 ebF-derived ECM were further confirmed by the growth and 
the maintenance of the properties of hESCs. In conclusion, these sequential 
experiments have provided solid evidences to establish autologous culture 
systems for hESCs expansion in both feeder-dependent and feeder-free 
conditions.  
This study compares the supportive abilities of two autologous fibroblast 
cells derived from different approaches, with the traditional MEF feeder and 
feeder-free MatrigelTM, for long-term growth of hESCs. This comparison helps 
to verify and standardize the autologous culture of hESC culture in future (Fu 
et al., 2009). This is also the first study to develop a feeder-free, xeno-free and 
serum free culture system for hESC culture by utilizing ECM substrate 
extracted from autologous fibroblasts. This finding facilitates the future 
preparation of hESCs for both pre-clinical and experimental applications.   
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  However, this study also found that the autologous culture system is not as 
stable as the traditional MEF culture system because of more 
spontaneously-differentiated hESCs. This suboptimal culture condition 
provided by autologous feeders may lead to the loss of pluripotency of hESCs 
in long run if without being carefully handled. Therefore, in this study, the 
hESC colony morphologies were carefully examined, and the colonies with 
differentiated signs were removed by “micro-selection”. However, for future 
large-scale propagations, improvements are needed to increase and stabilize 
the supportive abilities of the autologous feeders for hESC culture.  
  In the current experiment, the media to derive H9-F cells were not totally 
animal component-free. Other than the possibility of xenogenic pathogen 
contamination, there is a risk of immune rejection after the hESCs 
transplantation, because xeno-antigens might have been loaded onto the 
surface of hESCs during the co-culture with those contaminated H9-F. 
Therefore, to achieve a clinical grade of hESCs, the animal component-free 
media for feeder cell derivation and hESCs expansion need to be further 
refined.  
In the present testing system, the H9 ebF were seeded on human collagen 
type IV-coated plates to extract ECM. The various sources of human collagen 
type IV may cause batch variation of the supportive abilities of ECM. To avoid 
the confounding effects of collagen type IV, the supportive effects of 
autologous ECM without the collagen type IV coating are worthy of being 
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investigated. So far, only a few of the autologous ECM components have been 
identified. The understanding of all the ECM components would help to 
standardize the hESCs culture condition and prepare for the large-scale culture 
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1)  Table showing the details of the number of cells for growth curve analysis 
of H9 ebF and H9 dF from P2 to P20. 
Passage (P) number H9 ebF (x106) H9 dF (x106) 
P2 0.81 0.91 
P3 1.4 1.66 
P4 1.74 1.74 
P5 1.51 1.7 
P6 1.86 2.1 
P7 0.97 1.87 
P8 1.29 1.28 
P9 1.15 1.09 
P10 1.22 1.24 
P11 1.04 1.8 
P12 1.68 0.89 
P13 1.48 0.83 
P14 2.46 0.65 
P15 2.09 0.63 
P16 2.46 0.86 
P17 1.63 0.6 
P18 1.85 0.71 
P19 1.61 0.81 





















2)  Table showing the doubling time of H9 ebF and H9 dF from P2 to P20. 
Passage (P) number H9 ebF doubling time (h) 
H9 dF doubling time 
(h) 
P2 103.4492 83.33927 
P3 48.47092 41.59005 
P4 40.02029 40.02029 
P5 45.15385 40.78085 
P6 37.98866 34.77607 
P7 75.30934 37.83424 
P8 52.65579 53.09171 
P9 59.91842 64.03824 
P10 55.94922 54.94757 
P11 68.14416 38.9611 
P12 41.17907 86.55123 
P13 45.98884 98.47053 
P14 31.32262 190.2187 
P15 34.89212 215.9414 
P16 31.32262 92.02353 
P17 42.23191 273.7284 
P18 38.14518 142.3232 
P19 42.67778 103.4492 

























3) Table showing the normalized concentration of secreted FGF-2 in H9 
ebF- and H9 dF-conditioned medium after ELISA analysis.  
 
Cells Mean STD Cells Mean STD 
H9 dF P2 139.3342 26.55755 H9 ebF P2 84.82689 41.53262 
H9 dF P3 102.3904 47.572 H9 ebF P3 110.8197 37.06342 
H9 dF P4 169.4413 34.25128 H9 ebF P4 275.6208 20.75693 
H9 dF P5 115.5462 82.1093 H9 ebF P5 442.2026 43.7563 
H9 dF P6 187.5388 94.94901 H9 ebF P6 370.7733 35.59377 
H9 dF P7 193.8588 64.5081 H9 ebF P7 332.3182 35.64507 
H9 dF P8 100.5027 68.49873 H9 ebF P8 270.5126 30.97087 
H9 dF P9 111.0286 57.04656 H9 ebF P9 288.0978 8.109131 
H9 dF P10 90.60627 30.51268 H9 ebF P10 323.9589 42.91505 
H9 dF P11 137.6712 31.74526 H9 ebF P11 472.5619 51.80737 
H9 dF P12 208.8197 28.20905 H9 ebF P12 513.9416 110.7961 
H9 dF P13 135.169 24.31945 H9 ebF P13 488.4698 4.85699 
H9 dF P14 89.17351 26.63748 H9 ebF P14 553.4046 6.481853 
H9 dF P15 96.62433 26.40968 H9 ebF P15 590.0273 1.776509 
H9 dF P16 223.7503 127.4883 H9 ebF P16 495.8254 42.4272 
H9 dF P17 132.0488 43.58178 H9 ebF P17 341.1012 24.09215 
H9 dF P18 130.1573 64.62667 H9 ebF P18 311.7736 48.74971 
H9 dF P19 195.4701 12.98138 H9 ebF P19 641.3067 15.3471 

























4) Teratoma of H9 hESCs after cultured in various culture systems. 
 
A B C D 
Appendix 4.  Teratoma formation of H9 hESCs. (A). Teratoma 
specimen isolated from SCID mice after 9 weeks of injection with 
MEF-supported H9 hESCs. (B). Teratoma specimen isolated from 
SCID mice after 9 weeks of injection with Matrigel-supported H9 
hESCs. (C). Teratoma specimen isolated from SCID mice after 11 
weeks of injection with H9 ebF-supported H9 hESCs. (D). Teratoma 
specimen isolated from SCID mice after 9 weeks of injection with H9 
dF-supported H9 hESCs. 
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